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SUMMARY
(a) A significant decrease in the extent of the redox state 
shift after ethanol administration was obtained in chronic 
ethanol treated normal and ascorbic acid deficient guinea, pigs, 
compared with their respective controls.
(b) This was not due to differences in blood ethanol concentration 
between acute and chronic ethanol treated animals, as the 
theoretical zero time blood ethanol concentration was the same in 
all the groups of animals.
(c) The decrease in the redox state shift after chronic ethanol 
administration may represent metabolic adaptation to ethanol at 
the mitochondrial level. As. this was achieved after a relatively 
short period of exposure to ethanol, it is likely that it can occur 
in man after exposure to comparable, quantities of ethanol.
(d) Although the redox state is important in the regulation of 
ethanol elimination in vivo, the approximately 10 per cent decrease 
in its shift, after ethanol administration to chronic ethanol 
treated animals, had no effect on their rate of ethanol elimination.
(e) There was no statistical difference between the redox states 
of ascorbic acid deficient groups and their corresponding normal 
controls.
V
(a) Microsomal protein content and aniline hydroxylase and NADPH 
oxidase activities, were significantly reduced in ascorbic acid 
deficient guinea pigs, although catalase and "MEGS activities were 
unchanged. Cytochrome P-45Ocontent was also significantly 
decreased, but no change was observed in cytochrome b^ content.
(b) Although the half life of diphenylhydantoin was increased by 
36 per cent in the ascorbic acid deficient guinea pig, no change 
in the rate of ethanol clearance from the blood was found.
(c) Chronic ethanol treatment did not induce microsomal enzyme 
activities or increase cytochrome P-450 content.
(d) Phenobarbitone pretreatment of guinea pigs resulted in increases 
in liver/body wt, activity of aniline hydroxylase, cytochrome P-450 
content and microsomal protein, although this had no effect on the 
rate of ethanol clearance from the blood.
(e) As K30S activity was not dependent on cytochrome P-450 content, 
and did not parallel changes in the activity of aniline hydroxylase, 
it does not have properties associated with established microsomal 
drug metabolizing enzymes.
(a) A significant correlation coefficient (r = 0.88, P<0.001) was 
obtained when hepatic alcohol dehydrogenase activities of 12 patients 
with non-alcoholic liver disease were plotted against their 
corresponding leucocyte ascorbic acid content.
(b) The rate of clearance of ethanol from the blood of 11 healthy 
male volunteers was significantly increased after oral ascorbic 
acid supplementation.
(c) Hepatic alcohol dehydrogenase activity and leucocyte ascorbic 
acid content were measured in 35 patients with liver disease and in 
10 control subjects with duodenal ulcer. The patients with liver 
disease were divided into non drinkers, moderate drinkers and 
alcoholic/heavy drinkers.
(d) There was no significant difference in hepatic alcohol 
dehydrogenase activity between the groups with liver disease, but 
they had less than half the hepatic alcohol dehydrogenase activity 
of the control subjects.
(e) A correlation coefficient of r = 0.77 (P<0.00l) was obtained 
when the hepatic alcohol dehydrogenase activity of each patient 
with liver disease was plotted against its corresponding leucocyte 
ascorbic acid content. An insignificant correlation coefficient
r = 0.332 was found in the control subjects, who had no evidence 
of liver disease.
(f) When this was repeated with the liver disease patients divided 
according to their previous alcohol intake, significant correlation 
coefficients of r = 0.873 (P<0.001) for the non drinkers, r = 0.739 
(p<0.02) for the moderate drinkers, and r = 0.702 (P<0.005) for the 
alcoholic/heavy drinkers were obtained.
(g) The addition of ascorbic acid in vitro (0.5 mM to 10 mM) had no 
effect on the activity of alcohol dehydrogenase.
(h) The relation between hepatic alcohol dehydrogenase activity and 
leucocyte ascorbic acid content is probably a consequence of liver 
disease, as opposed to any specific effect of ascorbic acid status 
on alcohol dehydrogenase activity.
4. (a) A 4/0 incidence of the atypical form of human alcohol dehydrogenase 
was found in a Scottish population. This exhibited a biraodal 
distribution.
5. (a) The activity of the NAPPH dependent ethanol oxidizing system v/as 
increased in patients with liver disease. This was significant 
whether activities were expressed per mg protein or per g wet wt 
liver.
(b) It is suggested that the I'JADPH dependent ethanol oxidizing 
system maintains normal rates of ethanol metabolism in patients 
with liver disease. The greater activity of the NAPPH dependent 
system in patients with liver disease may compensate for the low 
alcohol dehydrogenase_activities found in these patients.
INTRODUCTION
Historical
The use by man of alcoholic drinks dates back to the very beginnings
of human civilisation. In all the ancient civilisations of which records
remain, their wealth was measured by production of corn, wine and oil.
The origin of these necessities being ascribed to the gods.
*
The manufacture of wine has developed from the distribution of the 
grape vine and is characteristic of a settled civilisation. The vine does 
not bear fruit till three years after planting, whereas a crop of com can 
be raised within a year. The possession of a vineyard thus becomes 
synonymous with a settled existence, and it seems probable that the 
invention of wine is synchronous with the birth of civilisation.
General
The metabolic effects of ethanol depend on the quantities consumed. 
Moderate quantities are relatively innocuous, and ethanol acts as a 
nutrient which can supply a large part of the caloric requirements of the 
organism. The consumption of ethanol, in quantities that are in excess 
of the upper limits of the mechanisms responsible for its metabolic 
elimination, leads to serious toxic effects and metabolic derangements.
The metabolism of ethanol can interfere with that of various 
foodstuffs and endogenous substrates, as they all share common metabolic 
pathways. Ethanol per se may also produce metabolic alterations by 
exerting a direct toxic effect on specific organs.
Site of Metabolism of Ethanol
Early in the 20th century, Batteli and Stern^ demonstrated that 
human liver was capable of oxidizing ethanol. The central role of the 
liver in the oxidation of ethanol was established using perfused liver,
9
which was shown to remove ethanol from the perfusion fluid , and by 
hepatectomy, which caused ethanol oxidation in dogs to decrease to very 
low levels^. Later work by Tygstrup et al4 in man, and Gordon^ in other 
species, has established that 70 - 95p of ethanol metabolism is accounted 
for by oxidation in the liver.
Enzynoiogy. of Ethanol Metabolism
In the liver there are three enzyme systems capable of oxidizing 
ethanol to acetaldehyde. These are alcohol dehydrogenase (ADE), catalase 
and the microsomal ethanol oxidizing system (ME03).
(i) Alcohol Dehydyo.genase (alcohol — NAD oxidoreductase EC IIII) is the
initial and rate limiting enzyme in the major pathway of ethanol
metabolism^. It is a cytosol enzyme and catalyzes the following reaction:
CH_CHo0H + NAT)* -— ■' ^ CTT CEO + KADH + H+ 
j * v 3
7 -12Backlin found the equilibrium constant of this reaction to be 8 x  10
at 20°C and ionic strength 0.1. The position of this equilibrium is very 
unfavourable for the oxidation of ethanol, as the change in free energy at 
physiological pH (AG, pH 7*4) is +4*9K cal/mole. Fortunately the 
oxidation of acetaldehyde to acetate has a very favourable change in free 
energy (AGabout -l^K cal/mole) which furnishes the free energy needed for 
the dehydrogehation of ethanol.' As acetaldehyde is oxidized to acetate, 
more ethanol can be oxidized to acetaldehyde and thus the equilibrium of
g
the ADH reaction can be maintained. . Theorell and Chance have proposed
the following reaction mechanism for ADH:
E + K A ] ) V = ^  E.NAD+
S.NAD+ + ethanol --- ^ E.NADH + H+ + acetaldehyde
E.NADH - - - ■ E + HADE
Experiments with purified ADH have shown that the rate limiting step in
this reaction is the dissociation of the E.NADH complex.
Horse liver ADH, the most extensively studied of the ADH enzymes, has
a molecular weight of 84000 with four atoms of zinc present in each 
g
molecule . Removal of two zinc atoms by dialysis, or addition of zinc
9complexing agents such as EDTA, abolishes enzyme activity . Human liver
ADH resembles horse liver ADH in many physicochemical and kinetic
properties. Its molecular weight is 8700&^ and it contains two atoms
11 12of zinc per molecule . H arris has proposed that the active enzyme 
consists of two similar polypeptide chains, each containing a reactive - 
SE group in a cysteine residue. Theorell and Bonnichsen1  ^have shown 
that the -SH group, together with zinc and other amino acid side chains, 
is involved in binding the substrate and coenzyme to each of the active 
centres within the quaternary structure of the active dimer. Human ADH 
differs in substrate specificity from horse liver ADH; it can oxidize 
methanol, ethylene glycol1 ,^ isopropyl alcohol, chloral hydrate and other 
pharmacologically ana toxicologically important compounds at relatively 
high rates'*'1.
ADH has been shown to exist in multimolecular forms; the number of 
ADH active bands which can be separated in liver homogenates by gel 
electrophoresis depends on the species1^. This heterogeneity of ADH has 
been investigated predominantly in horse liver, although at least seven
isoenzymes can be distinguished by electrophoretic and chromatographic
15 16
methods in human liver . Schenker et al have purified, isolated and
determined the subunit composition of six of these isoenzymes from human
liver. They have suggested that the isoenzymes are formed by combinations
of three subunits designated A, B and B1 to give six dimers AA, AB, BB,
BB1, B1B1 and AB1. Subunit B has been shown by Berger et al1  ^to exist
in two forms termed B^ and Bg. These subunits differ with respect to
one amino acid residue, which is located in a region of the subunit which
corresponds to the coenzyme binding site of horse ADH. B^ is considered
the subunit responsible for the atypical catalytic properties discussed
below.
Human liver ADH exhibits a polymorphism in addition to its heterogeneity'
this polymorphism is revealed by a bimodal distribution of the enzyme in
a population, when a screening test is used to differentiate between the
19
normal and atypical enzyme . The normal enzyme has a pH optimum of 10.8
while the atypical enzyme has a pH optimum of 8.5.
Development of liver ADH in the foetus and neonate has been described
20
for the human by Pikkarainen and Raiha , and for the rat and guinea pig 
21
by Raiha et al . Adult activities were found at 5 years of age in the
human, 18 days after birth in the rat and 6 - 8  days in the guinea pig.
In the human there are kinetic differences between adult ADH and that of
20
the foetus and infant
Since other alternative pathways for ethanol metabolism lead to the
formation of the same product, acetaldehyde, the proof of ADH participation
in vivo is indirect. One type of indirect evidence is the correlation
between in vitro and in vivo effects of known inhibitors of ADH. Pyrazole
given to rats in a dose of approximately 4mmoles/Kg shortly before
removal of the liver, inhibits ADH activity completely; the same dose
22
reduces the in vivo rate of ethanol metabolism by 80 - 100^ ♦ The
similarity of the kinetics of ADH activity in vitro, and of ethanol
dissappearance in vivo also furnishes indirect evidence for an in vivo
role for ADH in ethanol metabolism. The disappearance of ethanol from the
blood or whole body continues at a constant rate in most species until
the concentration in the body water has fallen to 2 - 5 mM, depending on 
23
the species . Calculation of the apparent Km from the non-linear
portions of the blood alcohol curves below these concentrations, yield
values which agree reasonably closely with those obtained in vitro with
23
ADH preparations from the same species , The Km values for the other
24
possible pathways of ethanol metabolism are much higher
The physiological role of ADH is to interconvert various endogenous
alcohols and aldehydes. Small amounts of endogenous ethanol have been
detected in the blood, tissues, and urine of subjects who have not
consumed alcohol. Ethanol levels in the portal vein have been shown to
exceed those in the heoatic artery, and oral administration of antibiotics
* 25
can reduce these levels . This suggests that hepatic ADH functions as a 
detoxification mechanism for low levels of ethanol formed in the 
intestinal tract.
26
(ii) Catalase. Keilin and Hartree showed that catalase, in the presence
of a H 0 generating system, can catalyze the following reaction:
? ^ catalase
CH CH OH + H 0 ------- ► CH CHO + 2H 0
3 2 2 2 3 2
In this reaction catalase is acting as a peroxidase as ethanol is the
hydrogen donor. The above reaction has been demonstrated in rat liver
27
homogenates, by Lundquist et al . Large amounts of catalase are found
in the body, and as there are also various peroxide generating systems
present, it is possible that some oxidation of ethanol could occur by this
28
route in vivo. Smith using the catalase inhibitor 3-amino-l,2,4-triazole
obtained 90$ inhibition of catalase activity in vivo, although the rate
of oxidation of ethanol both in vivo and in vitro was unchanged. Under
normal in vivo conditions the rate of formation was found to be too
rate limiting to permit even a small fraction of ethanol metabolism to
29
take place via peroxidation , therefore a system which can produce
and can be enhanced with chronic ethanol treatment is required. Such a
30
system has been described by Carter and Isselbaqher , who demonstrated an 
increase in microsomal NADPH oxiqase activity in rats that were chronically 
exposed to ethanol. This system could therefore lead to an increased 
metabolism of ethanol by catalase, without any increase in catalase activity
as most investigators have failed to show an increase in catalase activity
31 . 32
after chronic ethanol treatment . Aebi has shown that the production
of H O  is in fact the rate limiting steo in the catalase reaction.
2 2
Although an increase in the activity of NADPH oxidase has been shown,
31
Videla et al have calculated that the resulting increased production of 
H^Qg, and subsequent - peroxidation of ethanol by catalase, could only 
account for 10 - 20^ of the increased rate of ethanol metabolism in 
chronic ethanol treated rats. The role of catalase in NADPH dependent 
ethanol oxidation is discussed below.
33
(iii) Microsomal Ethanol Oxidizing System. Orme-Johnson and Ziegler
demonstrated that the mixed function oxidase system in mammalian liver
microsomes, which plays a major role in the metabolism of many drugs,
could also catalyze the NADPH and 0 dependent oxidation of ethanol and
2
methanol to their corresponding aldehydes, in vitro, by the following 
reactions -
CH ,,CHo0H +. NADPH + H+ + 0o ^ C H qCH0 + NADP+ + 2H_0
O ft ft Q Z
As cytochrome P-450 is involved in microsomal hydroxylase reactions, CO
would be expected to inhibit this reaction by binding to cytochrome
P-450. This was not found by Orme-Johnson and Ziegler, although they
demonstrated inhibition of the reaction with azide and cyanide. In a
similar system, termed the microsomal ethanol oxidizing system (ME03),
.34
Lieber and De Carli demonstrated ethanol oxidation to acetaldehyde.
This system differed from the one outlined above by being sensitive to
CO inhibition, and in oxidizing ethanol at a higher rate than methanol.
Other workers have shown that a Senera^^ -nS system can be substituted
for NADPH or a NADPH generating system, although direct addition of H O  
35 2 2
was ineffective . MSGS has been widely studied because of its possible
16
involvement in a common pathway for ethanol and drug metabolism, although
a controversy exists as to its true nature* Lieber and De Carli support
the concept that MEOS is a true microsomal oxidase similar to the
microsomal drug oxidase system; whereas other workers consider MEOS
activity to be a product of microsomal NADPH oxidase activity, which
generates and catalase activity, which utilizes this generated
to peroxidate ethanol to acetaldehyde.
Lieber and De Carli have utilized the following observationsto
support their concept of MEOS. MEGS, like other microsomal drug
34
metabolizing enzymes, requires NADPH and oxygen and is not inhibited by
34
pyrazole at concentrations which inhibit ADH . Thus MEOS activity is
considered to be separate from ADH activity, because of this difference in
pyrazole inhibition. Drugs which are oxidized by the microsomal drug
metabolizing system bind to microsomes and produce spectral changes of
36
two distinct types (I or II) (Fig l). As the addition of ethanol to
37
microsomes produces a modified type II binding spectrum , this suggests
that ethanol can interact with microsomes in a similar manner to drugs.
Phenobarbitone pretreatment, which induces microsomal enzyme activities,
38 39
also increases the activity of MEOS . Lieber and De Carli showed that
the in vivo administration of pyrozole to rats had no effect on MEOS or
NADPH oxidase activity, but inhibited catalase activity by 90$. They
therefore concluded that catalase was not required for the function of
MEOS. The differentiation between catalase and MEOS activity was also
demonstrated by the addition in vitro of azide, ,a powerful' catalase inhibitorj
40
to microsomes of pyrazole pretreated rats. Lieber and De Carli obtained 
an approximately 95$ inhibition of H^O^ dependent microsomal ethanol 
oxidation using these inhibitors, while NADPH dependent microsomal ethanol
H y d roxy l a t ed  Drug
I n te r m e d i a t e
Complex
Reduced
F l avopro te i n
Drug
T y p e
NADP
450
Re d uc ed
P450
NADPH Flavoprotein
Drug
Type
H
Fi g . I
Type I and Type II substrates metabolized by 
cytochrome P-450 dependent drug metabolizing system
oxidation was decreased by only 33%.
The concept of MEOS activity being a product of NADPH oxidase and
catalase activity is supported by many workers, who base this alternative
system on the following observations. Similarities between MEOS, and the
NADPH oxidase and-catalase system, with resoect to requirement for NADPH
41
and oxygen have been found by Thurman et al . These authors showed that 
both systems had identical oxygen concentrations for half maximal rates, 
and both systems were sensitive to CO inhibition. They also demonstrated 
that microsomal acetaldehyde production, in the presence of either an NADPH 
or HgOg generating system, exhibited identical characteristics with respect 
to ethanol concentration for half maximal rates (l2mM). Formate, a 
peroxidatic substrate, was shown to competitively ' inhibit acetaldehyde 
production in both generating systems; and catalase inhibitors such as 
azide also inhibited acetaldehyde production in both types of generating 
system.
42
Carter and Isselbacher have also added to the evidence for the 
involvement of catalase in MEOS activity. They noted that the combined use 
of azide and pyrazole, inhibited both catalase and the system used to 
generate an<^  this combination is therefore unsuitable for use in
differentiating between and NADPH dependent ethanol oxidation.
Instead they used catalase inhibitors such as cyanide in vitro, and 
aminotriazole in vivo, and demonstrated that NADPH dependent ethanol
oxidation was inhibited.
43
Khanna et al have also concluded that microsomal oxidation of 
ethanol depends on catalase like activity, again basing this on 
observations that catalase inhibitors markedly reduced NADPH dependent 
ethanol oxidation. They also showed that E 0 and barium peroxide could
both replace NADPH in supporting ethanol oxidation.
Lastly, the type II binding spectrum of ethanol with microsomes, is
44
considered by Imai and Sato to be a direct action of ethanol on
microsomal membranes, rather than a true substrate binding effect*
The above observations, although depending on the specificity of
enzyme inhibitors, suggest that catalase is involved in NADPH dependent
42-
ethanol oxidation, and Carter and Isselbacher have proposed the
following mechanism:
NADPH + 09 NA]?PH >Hr,Q 
* oxidase * <•
B202 + CH3CK2OH e-aT alase>CH3CH0 + 2H,,0
NADPH oxidase produces HgO^, which is then used in the peroxidative
conversion of ethanol to acetaldehyde catalyzed by catalase.
In conclusion, although most studies have involved the use of non
specific enzyme inhibitors to differentiate between the various enzyme
reactions involved, the above observations suggest that MEOS activity is
probably the result of NADPH oxidase and catalase activity*
The quantitative role in vivo of MEOS is unclear, as it cannot account
for all of the increase in ethanol clearance rate shown in chronic ethanol 
31
treated rats • Studies on the in vivo significance of MEOS have again 
depended on the use of non specific inhibitors. In most studies ADH 
activity was unchanged, and little work has been done on the quantitative 
significance of MEOS in experimental and pathological conditions where 
ADH activity is decreased.
Factors Affecting the Rate of Ethanol Metabolism
46
(a) Sthanol Concentration* Widmark has shown that ethanol is eliminated
at a constant rate over a wide range of concentrations, the rate only
decreasing when blood ethanol concentrations have fallen to about
46 48
9mg/lOOml) in .humans , and 4-2mM(l8-9mg/l00ml) in dogs . These
concentrations are close to the MLchaelis constant of isolated purified
ADH, therefore ADH activity is thought to be responsible for this steady
rate of ethanol elimination.
(b) Changes in the Rate of the ADH Reaction. A number of factors may 
influence this reaction, (i) the activity of ADH, (ii) the rate at which 
the mitochondrial shuttle system can transport reducing equivalents from 
NADH, produced by ADH, into the mitochondria, (iii) the rate of oxidation 
of NADH in the mitochondria.
(i) Activity of ADH. Decreases in ADH activity produced by inhibition
22
with pyrazole, lead to decreased rates of ethanol clearance in rats j
although subjects possessing the more active atypical form of ADH have
49
normal rates of ethanol clearance . The activity of ADH is therefore not 
the sole determining factor which regulates the ADH reaction.
(ii) Transfer of Reducing Equivalents. More than 90$ of the oxygen 
uptake of liver occurs in the mitochondria. NADH cannot penetrate the 
mitochondrial membrane and a carrier or shuttle system is used to transfer 
the reducing equivalents from NADH into the mitochondria. The malate — 
aspartate system has been postulated as the shuttle system responsible,
as malate dehydrogenases are present in both the cytoplasm and mitochondria, 
Oxaloacstate is reduced to malate in the cytoplasm, and malate is then 
transported into the mitochondria and reoxidized to oxaloacetate. One
equivalent of NADH is thus produced inside the mitochondria. As
50
oxaloacetate permeates the mitochondrial membrane at a slow rate , this
system has been slightly altered to incorporate an intermediary
51
transaminase system (Fig 2). Transaminase inhibitors have been used to
study the involvement of the malate - aspartate shuttle during ethanol
metabolism. The administration of transaminase inhibitors reduced the
ethanol elimination rate by 50$, as well as preventing the Dassage of
52
reducing equivalents into the mitochondria . Under normal conditions this
system is not rate limiting during ethanol metabolism, as the NADH
concentration inside the mitochondria increases by the same proportion as
that in the cytoplasm. NADH added to the complete system is oxidized at a
rate similar to that of ethanol oxidation in vivo. The mitochondrial
shuttle system can be induced after chronic ethanol treatment, as Rawat and 
53
Kuriyama have shown an increase in mitochondrial permeability to NADH 
in chronic ethanol treated mice.
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(iii) Oxidation of NADH. Videla and Israel have shown that the 
rate of ethanol metabolism by the liver depends on the rate of mitochondrial 
reoxidation of NADH, produced during ethanol oxidation. This was 
demonstrated using uncouplers of mitochondrial oxidative phosphorylation, 
such as 2,4 - dinitrophenol or arsenate, which increased the rate of 
ethanol metabolism of normal rat liver slices, indicating that NADH 
reoxidation was in fact rate limiting.
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Mitochondrial shuttle system for the transfer of 
reducing equivalents, produced from the 
dehydrogenation of ethanol in the cytosol,into 
the mitochondria.
Sffsct of Ethanol on Metabolic Processes
It is important to differentiate between metabolic effects 
secondary to the physiological action of ethanol and those produced by 
its metabolism* The metabolism of ethanol leads to the formation of a 
large amount of 2-*carbon residues, which enter common metabolic pools 
and as a consequence can alter other metabolic pathways.
During ethanol metabolism the supply of cofactors, which are shared 
by other pathways involved in the oxidation of endogenous substances, is 
restricted. The hepatocyte undergoes a change from an oxidative to a 
reductive internal environment, which is reflected in the cytoplasmic, 
microsomal and mitochondrial compartments of the cell. This change in the 
redox state of the various cellular compartments influences many metabolic 
pathways.
Changes in NAD Concentration. The increase in the ratio of the 
reduced to the oxidised form of NAD in the liver, which takes place after 
ethanol ingestion, can be demonstrated with very small concentrations of 
ethanol. Direct determination of NAD** and NADH in extracts from liver 
tissue showed a definite increase in NADH, although the total amount of
ss
the coenzyme did not change . • The initial reduction of NAD occurs within 
the cytoplasmic compartment, where ADH is located.
As NAD and NADH exist in both free and bound forms, the amount of 
free coenzyme must be measured indirectly. This is done by measuring 
certain metabolites which form redox pairs, and are assumed to be in
-j-
equilibrium with the free NAD and free NADH of the cell. Lactate and
pyruvate are used as a measure of the cytoplasmic free NAD*/free NADH ratio,
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which is termed the redox state . Similarly, the measurement of 3 - 
hydroxybutyrate and acetoacetate can give .a measure of the intramitochondrial 
redox state. • .
Tricarboxylic Acid Cycle. The presence of ethanol causes a marked
57
depression of the rate of COg formation from the liver. Fcrsander ,
using liver slices, showed that the respiratory quotient (RQ) decreased
from 0.74 to 0.02 when ethanol was present, without there being any
change in the oxygen uptake of the liver. It is possible to differentiate
between COg production from the TGA cycle and that produced from other
cycles using radioactive labelled glucose. Using this technique,
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Williamson et al have demonstrated that the TCA cycle is inhibited by
75^ during ethanol metabolism. This is thought to be due to the
inhibition of isocitrate dehydrogenase by the presence of increased amounts
of NADH produced during ethanol metabolism.
Carbohydrate Metabolism. A major function of the liver is the
regulation of blood glucose concentration. The production of glucose from .
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pyruvate and other metabolites is known as gluconeogenesis. Krebs et al
have shown that ethanol inhibits gluconeogenesis from lactate but not
from pyruvate. When lactate is the gluconeogenic precursor, the ethanol
induced redox state shift prevents the conversion of lactate to pyruvate
and gluconeogenesis from lactate is inhibited.
The influence of ethanol on blood glucose concentration is dependent
on the nutritional stats of the organism; well fed and starved organisms
react in different ways. Under normal conditions in man, and in well
nourished animals, ethanol causes a slight Increase in blood glucose
concentration. This hyperglycemia is probably due to an Increase in the
breakdown of liver glycogen brought about by an increased release of
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adrenaline by ethanol . In the starved organism the blood glucose 
concentration Is derived exclusively through gluconeogenesis in the liver.
Animals that have been starved for a prolonged period (2 to 3 days) show
a pronounced fall in blood glucose concentration after ethanol 
PIadministration0 . ±n man this condition known as alcohol induced 
hypoglycemia may be a serious or even fatal consequence of ethanol 
consumption.
Lipid Metabolism. The accumulation of fat in the liver during ethanol 
metabolism is associated with the development of alcoholic liver disease. 
The majority of liver biopsy specimens from alcoholics show the presence 
of fatty infiltration. Unfortunately, no obvious relationship has been 
found to link the development of steatosis with necrosis and cirrhosis of 
the liver, as only about 10$ of alcoholics develope cirrhosis^. Ethanol 
can influence lipid metabolism in several ways. The 75$ reduction in the 
TCa cycle shown by Williamson et al^®, can affect the oxidation of lipids 
as they furnish a large part of the energy produced by the liver. Fatty 
acid synthesis may be directly accelerated by the increased extramitoch- 
ondrial concentration of NADH and NADPH. Nikkila and Ojala^ have shown 
that the reduction of dihydroxyacetone phosphate by NADH leads to 
increased amounts of glycerophosphate in the liver after ethanol 
administration, and this may facilitate the esterification of free fatty 
acids to triglycerides. It is also suggested that a large dose of 
ethanol may produce a non specific stress situation which leads to 
mobilisation of depot fat®^. All these mechanisms can therefore give 
rise to increased amount of triglycerides in the liver.
Ascorbic Acid
65
The isolation of L-ascorbic acid was carried out by Zilva , who
established the general properties of the vitamin. He shoved that the
vitamin, isolated from lemon juice by precipitation with lead acetate,
was a nitrogen free substance with powerful reducing properties. The
physiological activity appeared to be associated with this reducing power,
66
although freshly oxidized solutions still retained their activity . This
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anomaly was resolved by Tillmans et al who demonstrated that the
vitamin could be reversibly oxidized to dehydroascorbic acid, and that
both the oxidized grid reduced forms were physiologically active, L-ascorbic or
L-threo-hexono-l,4-lactone-2-ene is an optically active (|aj +23° in water),
white crystalline solid melting at 192°C. It reacts as a monobasic acid •
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with a pK = 4.25 in water , although a second ionisation constant
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pKa2 = 11.79 has also been reported . It has been suggested that the
in vivo role of ascorbic acid is related to its ease of oxidation and
reduction, as both the reduced and oxidised forms are found in tissues
with high metabolic activity. A role in electron transport has therefore 
70
been suggested
Collagen Formation. The formation and maintenance of normal collagen
requires L-ascorbic acid; if ascorbic acid is absent a non-fibrous collagen
71
precursor is formed instead of fibrous collagen. Robertson has
suggested that ascorbic .acid is required for the hydroxylation of proline
to hydroxy-proline and this is then involved in the synthesis of collagen.
It is thought that the hydroxylation of proline involves the formation
71 *
of a free hydroxyl radical from ascorbic acid
Action of Enzymes. Ascorbic acid can activate enzymes such as liver 
72 73 74
esterase and catalase , but inhibits urease from plants. The
inhibition of urease by ascorbic acid takes place when copper ions are
j_ O-j-
present; Cu° is reduced to Cu^ by ascorbic acid and this ion has a
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greater affinity for the -3H groups of the enzyme . Ascorbic acid has 
no effect on enzymes when metal ions are absent, but it can enhance the 
inhibitory power of metal ions when they are present.
Drug Metabolism. The activity of liver microsomal drug metabolizing 
enzymes is influenced by many factors such as age, sex, strain and species, 
as well as the nutritional state of the animals. With respect to nutrition, 
the function of ascorbic acid in maintaining drug metabolism has been 
widely studied. Most early studies were in vivo investigations, which 
showed decreased metabolism of a large number of drugs in vitamin C 
deficient (scorbutic) animals. More recently the underlying biochemical 
basis of this decrease in drug metabolism in vitamin C deficiency has been 
studied.
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• As early-as 1941 Richards et al demonstrated an increase in
pentobarbitone sleeping time in scorbutic guinea pigs, compared with
normal controls. The administration of ascorbic acid was found to return
the pentobarbitone sleeping time of the scorbutic guinea pigs to normal
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values. Axelrod et al also showed a significant increase in the plasma
half life of acetanilide, aniline, and antipyrine in scorbutic guinea pigs.
It was therefore established that the rate of metabolism of various drugs
was markedly reduced in vitamin C deficiency, but the biochemical basis
for this decrease was unknown.
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In 1961 Conney et al observed that, guinea pigs fed on a vitamin C 
deficient diet for 10 - 11 days, and showing no obvious signs of scurvy, 
were sensitive to the muscle relaxant, zoxazolamine. The increased 
duration of this drug in. vivo could be explained by a decrease in its 
oxidation, as liver microcomes prepared from scorbutic guinea pigs showed
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decreased rates of oxidation of the drug in vitro. Leber et al , in 
1959, demonstrated that liver microsoraes from scorbutic guinea pigs 
showed significant decreases in the demethylation of aminopyrine, 
hydroxylation of acetanilide, and- cytochrome P-450 content. There was no 
change in cytochrome bg content. The microsomal enzyme inducers 
phenobarbitone and 3- methylcholanthrene, were also shorn to induce the 
activity of the mixed function oxygenases in scorbutic guinea pigs. These 
workers also showed that the prior administration of ethionine could block 
this induction of mixed function oxygenase activity. These results 
indicate that the system for de novo synthesis of microsomal enzyme protein 
is operable in the scorbutic guinea pig.-
MATERIALS AND METHODS
Materials
Ascorbic Acid B.P. for administration to animals was supplied by 
Koch-Light Laboratories Ltd., Colnbrook, Bucks, England. Ethanol 
solutions for animals were made up with Absolute Alcohol B.P. 99.9^ v/v, 
supplied by James Burrough Ltd., Fine Alcohols Division, 60 l-fontford Place 
London S.E.11. n-Propanol was supplied by Reeve Angel Scientific Ltd.,
14 New Bridge Street, London E.C.4, from their chromatographically tested 
range. Phenobarbitone B.P. as the sodium salt (Macarthys Ltd., Chesham 
House, Chesham Close, Romford RML 4JX, Essex) and Phenytoin (Parke-Davis) 
were supplied by the pharmacy, Stobhill General Hospital, Glasgow. Enzyme 
and coenzymes were supplied by the Boehringer Corporation (London) Ltd., 
Bilton House, Uxbridge Road, Ealing, London, W5 2T2. Porapak Q for gas- 
liquid chromatography was obtained from Waters Associates Inc. Framingham, 
Ifessachusetts, U.S.A. All other reagents were ‘Analar’ grade, and were 
supplied by B.D.H. Chemicals Ltd., Poole, England.
Methods
Vitamin C. Deficient Diet
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The diet used was based on that of Woodruff et al and had the
following percentage composition, oat flakes 39; dried skimmed milk 30;
wheat bran 20; vegetable oil 8; cod liver oil 2; and NaCl.l. Additions to
this diet were made to improve its mineral and vitamin content. These
80 81 
additions were similar to those made by Ginter , and Hughes and Hurley
who used diets with similar percentage compositions as that of Woodruff et al
The diet was supplemented with 0.5g MgQ and 0.5g salt mixture/lOOg diet as
81 80
recommended by Hughes ana Hurley ana Ginter respectively.
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The salt mixture of Ginter contained (g), CaCO 60; K HP0, 64.5;
& ' 3 2 4
NaCl 33.5; MgSO 20.4; CaHPO 15; ferric citrate 5.5; lfaSO^HgO 1.0;
XI 0.16; CuSO,5H0 0.06; and ZnCl 0.05.
4 2 2 g0
The following vitamin supplement, again as described by Ginter , was
also added/lOOg diet, nicotinamide 20rag; calcium pantothenic 3mg; thiamine
hydrochloride 2mg; riboflavin 2mg; folic acid 2mg; and pyridoxine
hydrochloride lmg.
Each animal was given a weekly supplement of 0.05ml cod liver oil by
81
intubation, and lOg of hay as described by Hughes and Hurley .
When supplemented with L-ascorbic acid, the diet supported normal 
growth of guinea pigs. Without ascorbic acid the guinea pigs became 
scorbutic.
Measurement of Ascorbic Acid in Guinea Pig Liver
Total liver ascorbic acid was measured by the 2,4-dinitrophenylhydrasine
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method of Roe and Kuether as modified by Bessey et al . The, advantage
of this modified method is that a large number of samples can be analyzed
at the one time. As ascorbic acid is stable in trichloroacetic acid,
whether or not the extract is separated from the protein precipitate,
deproteinised samples can be left overnight in a fridge. A second
advantage of this method is that ascorbic acid is oxidized to dehydroascorbic
acid by cupric ions present in the 2,4-dinitrophenylhydrazine-thiourea-ccpper
sulphate reagent, and a separate oxidation step is therefore not required.
Principles and Specificity. Ascorbic acid is oxidized, by cupric ions, to
dehydroascorbic acid which couples rapidly with 2,4-dinitrophenylhydrazine
in ION HgSO^, forming a bis-2,4-dinitrophenylhydrazine derivative of
dehydroascorbic acid (Fig 3). This derivative forms a highly stable
brownish-red colour when treated with 65$ H-SO,. and this can be measured
2 4
spectrophotometrically.
The specificity of the method is based on several principles (a) 
the colour is only produced by 2,4-dinitrophenylhydrazine derivatives of 
6-carbon and 5-carbon sUgarlike compounds.
(b) the rate of coupling with dehydroascorbic acid is much faster 
than with sugars or other sugarlike compounds.
(c) interfering chromogen formation is avoided by working with fairly 
dilute solutions of tissue extracts, and by carrying out the coupling 
reaction at a relatively low temperature (37°C).#
(d) the coupling reaction is carried out in the presence of the 
reducing agent thiourea, which contributes to the specificity of the method.
The colour formed after the coupling with 2,4-dinitrophenylhydrazine
+ 2
o=c—
I
° = ?
° = ?
H— C -
I
HO—C—H
I
CHjOH
Dehydr oas corbic 2 ,4-Dinitro-
acid phenylhydrazine
H 0 = 0
N—N = C
N—N = C
O  +
H H— C —
NQa H O -C — H 
I
CHaOH
Bis-2 ,4-dinitrophenyl- 
hydrazine derivative
2 HaO
Fi g , 3
Ascorbic acid coupling with 2,4-dinitrophenylhydrazine.
and treatment with 65$ HoS0^, is due to a molecular rearrangement of 
the bis-2,4-ainitrophenylhydrazine derivative of dehydroascorbic acid.
The colour absorbs maximally at 500-550nm and. 350-J80xmu The chemistry 
of the coloured product is unknown, although it is established that it is 
produced by dehydrating conditions in a medium containing excess reducing 
agent. ^2^4 ac^3 as solvent and reactant, forming a very stable
reddish-brown product. Most potentially interfering substances (e.g. 
glucose, fructose, and pentoses) form a coloured product in H^SO^, but the 
colour fades in this reagent. After the addition of 65$ H^SO^ the sample 
should therefore be left for 30 minutes before reading on a spectrophotometer. 
Reagents
(1) 2,4-dinitrophenylhydrazine reagent containing 100 vols 2.2$ 
2,4-dinitrophenylhydrazine in ION H^SO^, 5 vols 5$ thiourea and 5 vols 
0.3$ CuSO,, .5H_0,
(2) 10$ trichloroacetic acid (TCA).
(3) 5$ trichloroacetic acid.
(4) 65$ H SO . To 30ml distilled water, add cautiously 70ml
(L ft
concentrated H SO .
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(0) Ascorbic acid standards. lOOmg ascorbic acid is dissolved in 
100ml 5$ TCA, giving a concentration of iOOOpg/ml. This is diluted with 
5$ TCA to give 10, 5, 2.5, 1.0 and 0.5yig/ml solutions.
Method. lg of liver is homogenised in 2ml distilled water (l in 3 dilution).
lml of the resulting homogenate is added to 19ml distilled water
(l in 20 dilution). To 5ml of this diluted homogenate is added 5ml of 10$
TCA (l in 2 dilution). The final concentration of TCA is 5$ and the final 
dilution of the tissue is 1 in 120. At this stage the tissue extract can 
be left overnight. The precipitated homogenate is centrifuged to. remove 
cell debris and denatured protein, and lml of the- resulting supernatant
is incubated with 0.3ml of the 2,4—dinitrophenylhydrazine-thiourea-copper 
sulphate reagent for 4 hours at 37°C. After cooling in an ice bath, 1.5ml 
of 65$ K?3C^ is added and the sample is left for 30 minutes. The optical 
density of the sample is then read at 520nm against a blank of 5$ TCA 
treated in the same way as the sample. A'calibration graph of 0.5, 1.0,
2.5, 5.0 and lOjug/ml is prepared using the ascorbic acid standards, which 
are treated in the same way as the sample. The concentration of ascorbic 
acid in the sample can then be obtained directly from the standard graph 
(Fig 4).
Calculation
The ascorbic acid content of liver tissue is calculated:
concentration(graph reading jag/ml) X dilution(l20) = jug ascorbic acid/g
wet weight liver.
O D
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F i g . 4 Ascorbic acid standard graph.
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The method of Bonnichsen and Brink as modified by Hillbom and 
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Pikkarainen was used. This modification includes a semicarbazide trap 
for the acetaldehyde produced by the alcohol dehydrogenase (ADH) reaction. 
As acetaldehyde is being continually removed by this trap, the reaction 
can proceed at its maximum rate:
ADH
CHqCHo0H + NAD  ► C H oCH0 + NADH3 2 3]
removed by semicarbazide trap
Reagents
(1) 1% Triton X-100 in 0.25M sucrose,
(2) Sodium pyrophosphate buffer (0.1M; pH9.0)
lOg Na4P207.10H20 
0,5g glycine
Dissolve in distilled water, adjust to pH9.0 with IN HC1 and make up to 
300ml with distilled water,
(3) Semicarbazide hydrochloride (2.2M)
Dissolve 5.0g semicarbazide HC1 in 10ml 2N NaOH, adjust to pK6,3/^6,5 with 
5N NaOH and make up to 20ml with distilled water.
(4) Ethanol (99.9$)
(5) NAD (approx. 0.03M)
Dissolve 20mg NAD in lml distilled water.
Method. The guinea pig is killed by cervical dislocation and its liver
removed and weighed. The following procedures are carried out at 4°C;
lg of liver is homogenised in 9ml of \% Triton X-100 in 0.25M sucrose,
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using a teflon piston-glass homogeniser. Raiha and Koskinen have 
previously demonstrated that this homogenising medium produces maximal ADH 
activities from liver. The homogenate is centrifuged for 30 minutes at
10,0G0g, and the resulting supernatant is then centrifuged for a further 
60 minutes at 100,000g in a 'Beckman L-2 ultracentrifuge. The supernatant 
obtained is used for the assay of ADH.
Assay
Experimental Cell Blank Cell
2.6ml pyrophosphate buffer 2.7ml pyrophosphate buffer
0.1ml semicarte aide solution 0.1ml semicarbazide solution
0.2ml NAD solution 0.2ml NAD solution
0.02ml supernatant 0.02ml supernatant
0.1ml ethanol ____
Total volume = 3.02ml 
Mix the cells and record the difference in their optical density at 340nm 
for 3 minutes, at 25°G, cn a Pye Unicam SP8000 split beam recording 
spectrophotometer. The blank cell is used to eliminate the background 
production of NADH by the supernatant. The increase"in optical density 
at 340nm, due to the formation of NADH, is therefore a measure cf ADH 
activity of the supernatant.
Calculation
— = U/ml supernatant 
e .d.v.
where
AE/min = optical density difference/min 
V  = assay volume - 3.02
2
« = extinction coefficient of NADH(6.22cm /nmole at 340nm)
d = light path in cm = 1
#
v - volume of supernatant = 0.02ml 
,* A 2/min X 24.28 = U/ml supernatant
for the specific activity: AS/min X 24.23____________   u/mg protein
mg protein/ml supernatant 
(l enzyme unit is equal to \p mole of NADH produced per minute at 25°C)
Freeze Clamping of Liver and Extraction of Metabolites
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The method of Williamson et al was used, the liver being prepared -
as follows. The guinea pigs are killed by cervical dislocation and their
livers rapidly removed and pressed between aluminium tongs precooled in
liquid nitrogen. The frozen liver Is pulverised in a mortar to a fine
powder, and liquid nitrogen is added frequently to keep the powTder frozen.
The powder is transferred to a weighed plastic centrifuge tube containing
2nl of frozen 30% (v/v) perchloric acid (HCIO^). After a rapid reweighing,
the tissue (l~2g) is mixed with HCIO^, care being taken that no thawing-
occurrs. Ice cold distilled water (5ml) is added and the mixture is
immediately homogenised in the centrifuge tube. This is continued for •
about 2 minutes until thawing is complete. Protein is removed by
centrifuging the preparation for 10 minutes at 30,000g, and the supernatant
is adjusted to pH5-6 with 1.4ml of 20% (w/v) KOH. After standing for 30
minutes in the cold, the precipitate of KCIO^ is centrifuged off. The
resulting supernatant is used for the determination of lactate, pyruvate,
acetoacetate and 3-hydroxybutyrate concentrations as described below.
Pyruvate and acetoacetate concentrations are determined in the same cell,
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by the method of Mellanby and Williamson , lactate and 3-hydroxybutyrate
89
concentrations are determined separately by the methods of Hohorst ,
90
and Williamson and Mellanby respectively.
Concentration of Pyruvate in Freeze Clamped. Liver
PrIncinia. • Lactate dehydrogenase (LDH) catalyzes the reduction of
pyruvate with reduced nicotinamide adenine dinuclsotide (NADH):
Pyruvate + NADH + H I----- - lactate + NAD+
The equilibrium of the reaction is very much in favour of lactate 
formation. Provided there is an excess of NADH the reaction proceeds 
rapidly to completion, and pyruvate is quantitatively converted to 
lactate. The decrease in optical density at 340nm due to the oxidation 
of NADH is measured, and this is used in the calculation of the pyruvate 
concentration.
Assay
Test cell Control cell
lml phosphate buffer (0.1M;pH7.0) lml phosphate buffer
2ial supernatant 2ral water
0.1ml NADH approx 6mM .. - 0.1ml NADH
(lOmg NADH/2inl distilled water)
Wavelength 340nra, light path 1cm, final volume 3.1ml.
The test cell is initially read three times against the control cell, 
with a 3 minute interval between readings. LDH (0.001ml) is added to both 
cells, and their contents mixed. Readings at 3,6 and 9 minutes after the 
addition of LDH are then taken. The concentration of pyruvate in the 
freeze damned liver is calculated as described below.
Concentration of Acetoacetate in Freeze Clamped. Liver 
Principle
3 - Hydroxybutyrate dehydrogenase catalyzes the reaction:
3 - Hydroxybutyrate + NAD**b n acetoacetate + NADH +
With a suitable excess of NADH, at least 03% of the acetoacetate is 
reduced to 3 - hydroxybutyrate, with the simultaneous oxidation of . an 
equivalent amount of NADH. Again the decrease in optical density at 
340nm due to the oxidation of NADH is measured.
Assay
Acetoacetate concentration is measured at the end of the pyruvate 
assay, when a constant optical density is obtained. 3-Hydroxybutyrate 
dehydrogenase (0.025ml) is then added to both cells, and the optical 
density is read at 5 minute intervals until the reaction stops (approx. 
20 mins). The concentration of acetoacetate in the freeze clamped liver 
is calculated as outlined below.
Concentration of Lactate in Freeze Clamped Ljver 
Principle
Lactate dehydrogenase (LDH) catalyzes the oxidation of lactate 
by NAD+ :
LDH
Lactate + NAD+ pyruvate + NADH + H *
As the equilibrium of the reaction lies far to the left, the reaction 
products must be removed to obtain quantitative oxidation of lactate. 
Protons are bound by using an alkaline reaction medium, and pyruvate is 
trapped as the hydrazone:
LDH
Lactate + NAD+ + hydrazine  ►pyruvate hydra zone + NADH + IL0 +
pH 9.5
The reaction is measured by recording the increase in optical density at 
340nm due to the formation of NADH.
Assay
Test cell Control cell
1.4ml Hydrazine/glycine buffer 1.4ml hydrazine/glycine buffer
(0.4M hydrazine; 1M glycine; pH9.5)
0.1ml NAD (60mg/ml; approx. 50mM) 0.1ml NAD
. 0.2ml supernatant ---
. 1.3ml H O  1.5ml H 0
2 2
The cells are mixed and allowed to come to room temperature; the optical 
density is read three times with 3 minute intervals and 0.01ml LDH is 
added to the test cell. On completion of the reaction (10-20 minutes) 
the optical density is read a further three times with 3 minute intervals 
between readings. The concentration of lactate is calculated as described 
below.
Concentration of 3-Hydroxybutvrate In Freeze Clamped Liver 
Principle
3-Hydroxybutyrate dehydrogenase catalyses the reaction: 
3-Hydroxybutyrate + NAD+ acetoacetate t NADH + IT"
In the presence of hydrazine, the acetoacetate is removed in the form of 
its hydrasone and the reaction proceeds quantitatively from left to right. 
The increase in optical density at 340nm due to the formation of NADH is 
a measure of the reaction.
Reagents
1. Tris buffer (0.1M; pH 8.5) .
Dissolve 1.21g tris-hydroxymethyl-aminomethane in 50ml distilled water, 
add 14.3ml 0.2N KC1 and make up to 100ml with distilled water.
2. Hydrazine buffer (pH 8.5)
Nix lml of hydrazine hydrate (99-100/S) and 5ml IN HG1 and dilute to 20ml 
with distilled water.
3. Nicotinamide adenine dinucleotide (approx 13mM)
Dissolve 20mgNAD in 2ml distilled v;ater.
Assay
Test cell Control cell
1.0ml hydrazine hydrate buffer 1.0ml hydrazine hydrate buffer
0.5ml tris buffer 0.5ml tris buffer
1.5ml supernatant 1.5ml distilled water
0.1ml NAD 0.1ml NAD
IHx the cells and read the optical density against the control cell three 
times with three minute intervals, between readings. Add 0.025ml 
3-hydroxybutyrate dehydrogenase (Boehringer Corp) and read the optical 
density at 10 minute intervals until the reaction stops (40-60 minutes).
The calculation of the concentration of 3-hydroxybutyrate in freeze clamped 
liver is described below.
Calculation of Concentrations of Metabolites
In the determination of these metabolites, the optical density 
occasionally changes slowly at the end of the reaction* The reason for 
this ’background creep1 is that the enzymes used for the determination of 
the metabolite concentrations may contain contaminating enzymes, which 
slowly react with other substances contained in the supernatant. This 
creep in optical density, which is linear with time, is superimposed on 
the entire reaction. It can be corrected for by graphically extrapolating 
to t0 (the time of the start of the reaction). Readings of the optical 
density are taken at three minute intervals, these are plotted against time, 
and the linear part of the curve is extended backwards to time t0. The 
point where it cuts the ordinate axis gives the correct end point of the 
reaction, and therefore the correct optical density change AE (Fig 5). 
Extrapolation to tQ was carried out for each of the metabolites measured.
No correction v/as made for the % yield of metabolites from the freeze 
clamped liver extracts.
Calculation.
AE x V =jumcles metabolite/g wet weight liver, 
e X d X A
where
AE = corrected optical density change 
V = volume of the assay mixture (ml)
A = portion of tissue (g)
= g tissue taken Xml supernatant used for assay
total ml supernatant
2
e = extinction coefficient of NADH (6.22 cm /umole at 340nm) 
d = light path of cell = 1cm
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Fig . 5
Extrapolation to to for determination of metabolites 
A: start of reaction with enzyme.
Calculation of NADH / NAD+ Ratios /
The ratio of the concentrations of free NADH and NAD+ ( ^ TADIlj / jNAD*J 
can be measured using the ratio of the concentrations or the oxidized and
reduced metabolites of suitable NAD- linked dehydrogenase systems which, 
because of their high activity, are in equilibrium with the free nucleotides, 
according to the equation:
Oxidized substrate.
Reduced substrate
[nadh]
= KjNAD+J
If K is known, the pIADHj / |naD+J ratio can be calculated from the 
concentrations of the substrates. The lactate- pyruvate system can give 
reliable values for the cytoplasmic NADkJ / jl^ ADj ratio, and the
3-hydroxybutyrate-acetoacetate system gives a measure of the intramitochondrial
JnaDh] /|naD+J ratio .
Cytoplasmic jNADHf   ^Lactate 1 y -j tn y t_0“"4
| NAD’1’} |pyruvate|_
and Intramitochondrial {nadh} = fp-Hydroxybutyrat e] ^ £.93 X 10*"^
{NAD"} £ acetoacetate]
The values of the equilibrium constants for the lactate-pyruvate and 3-
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hydroxybutyrate-acetoacetate systems were obtained from Williamson et al
Preparation.of Guinea Pig Liver Microsome5
The animals are killed by cervical dislocation and their livers 
perfused in situ with ice cold isotonic saline, to remove as much blood 
as possible from the tissue. All further procedures are carried out at 
'±°G, The livers $re quickly removed, blotted and weighed, and 1 in 4 
homogenates in 1.15$ KC1 are prepared using a teflon piston glass 
homogeniser. The homogenate is centrifuged for 10 minutes at 900g to 
remove cell walls and nuclei, and the resulting supernatant is centrifuged 
at 20,000g for 15 minutes to remove mitochondria. The microsome containing 
supernatant, which is produced, is centrifuged at 105,000g for 60 minutes; 
the resulting microsomal pellet is washed, resuspended in 1.15$ KOI, and 
recentrifuged for a further 60 minutes at 105,000g. The final washed 
microsomal pellet is suspended in 1.15$ KCl to give a concentration of 6mg 
protein/ml, and this suspension is used in the following microsomal 
enzyme assays,' and estimations of microsomal electron transport components.
Estimation of Microsomal Electron Transport Components
Cytochrome P-450 and cytochrome be were measured in the same cell
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by the method of Omura and Sato .
Assay
2ml'of phosphate buffer pH7.0 (0.15M) and lml of microsome suspension
(6mg protein/ml) are added, in duplicate, to a test and reference cell,
giving a final concentration of 2mg microsome protein/ml in the cells.
The base line difference spectrum of the two cells is recorded between
400 and 550nm in a Unicam SP8000 dual beam recording spectrophotometer.
All spectrophotometric measurements are carried out at room temperature.
Cytochrome bcr.o
5pl of a 0.2mM NADH solution is added to the test cell to reduce 
cytochrome bg. The difference spectrum between the test and reference 
cell is then recorded in the range 400 to 500nm. The same cells are 
used in the following assay.
Cytochrome P-450
CO is bubbled through the test cell for 20 seconds, 5mg of sodium 
dithionite is then added to both cells and CO is bubbled through the test 
cell for a further 20 seconds. The difference spectrum is recorded in the 
range 400 to 500nm.
Calculation of Electron Transport Component Concentrations
Cytochrome P-45Q Concentration
AE X V X 1000 = nmoles cytochrome P-450/mg microsomal protein€ X d X v X c 
where
A S  = difference in optical density between 450 and 490nm of difference spectrum
€ = molar extinction coefficient between 450 and 490nm = 91cnf*^
d = light path of cell = 1cm,
V = total volume of cell = 3ml.
v = volume of microsome suspension taken = 1ml
c = protein concentration of microsome suspension = 6mg/ml
Cytochrome be; Concentration
The difference in optical density between 423 and 500nm of the 
difference spectrum, divided by the concentration of protein/ml in the 
cell (2rng/ml) is used to express cytochrome b^ concentration.
Thuss-
” AE.0„ /mg microsomal protein423-500nm 423-500nm ' & v
Aniline Hydroxylase Assay
Microsomal aniline hydroxylase activity was determined by the method
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of Holtzman and Gillette • The assay is performed in duplicate in 20ml 
serum bottles containing:
0.5nvl Tris-HCl (150 ^ imoles, pH7.4 at 37°C)
0.5ml of a solution containing:
MgClg (15 pimoles) 
glucose-6-phosphate (30 pumoles)
NADP (1.5 jumoles)
glucose-6-phosphate dehydrogenase (2 units)
1 .0ml microsome suspension (6.mg protein/ml)
The serum bottles containing the above solutions are preincubated for 5 
minutes at 37°C, 1ml of 3mM aniline hydrochloride is then added, and the 
reaction incubated for 10 minutes at 37°C. Under these conditions the 
reaction is linear with respect to time and protein concentration. The 
reaction is stopped by placing the bottles in an ice bath. The amount of 
p-aminophenol formed during the reaction is determined by adding a 2.6ml 
portion of the incubation medium to a 45ml stoppered tube containing 25ml 
diethyl ether and lg of solid NaCl. The tubes are then shaken vigorously 
by hand. A 20ml portion of the ether phase is transferred to a second 
45ml stoppered tube and 1.6ml of 1% aqueous phenol, followed by 0.4ral of 
0.5M KjPO^ is then added. The tubes are shaken, the colour allowed to 
develope for 20-30 minutes, and the optical density of the aqueous phase 
is read at 650nm against a blank. The blank is prepared from an assay 
which contains 1.0ml of 1.15$ KOI instead of the microsome suspension.
It is extracted in the same manner as described above, and the aqueous phase 
is added to a cell which is used as the blank. The aqueous p-aminophenol 
samples are read against this blank cell.
A standard graph of optical density against p-aminophenol concentration 
is obtained in the following manner. Solutions of p-aminophenol are 
prepared so that 1.0ml contains 25, 50, 75 and 100 nmoles of p-aminophenol. 
1 .0ml of each of the prepared p-aminophenol solutions is diluted with 2.0ml 
of water and is extracted in the same manner as described above for the 
incubation medium. A standard graph is constructed by plotting the optical 
density of the p-aminophenol standards against the number of nmoles of 
p-aminophenol they contain/ml. As the standards are diluted and extracted 
in the same manner as for the assay samples, the amount of p-aminophenol 
produced in each assay can be obtained directly from the standard graph 
(Fig 6). The standard graph does not go through the origin because of the 
slight absorbance of the blank used. Aniline hydroxylase activity is 
expressed as nmoles p-aminophenol produced/mg microsomal protein/hour at 
37° G.
nmoles/ml
Microsomal Ethanol Oxidizing System (MBPS) Assay
34
M20S activity was determined by the method of Leiber and Be Carli 
In this assay the activity of KE03 is determined by measuring the amount 
of acetaldehyde produced. Acetaldehyde is trapped by a semicarbazide 
system, and the optical density of the resulting acetaldehyde-semicarbazcne 
complex gives a measure of the amount of acetaldehyde produced by MEOS.
Assay
0*2ml phosphate buffer pH7.4 (80 pmoles)
0.5ml microsome suspension (equal to 3mg microsomal protein)
0.2ml NADPH generating system containing:
0.3 yimoles NAD?
5.0 juraoles MgClg
20.0 pinoles Nicotinami.de
8.0ymoles Sodium isocitrate
0 .01ml Isocitrate dehydrogenase (0.2 units)
The assay is carried out in duplicate in Thunberg tubes which contain
0.6ml of 0.015M semicarbazide HC1 in 0.162-1 phosphate buffer pH7.0 in their
side arms. Thunberg tubes containing the above assay solutions are
preincubated for 5 minutes at 37°C, 0.1ml ethanol solution (SOyimole)
is then added to each tube and they are incubated for 10 minutes at 37°C.
The reaction is stopped by the addition of 0.5ml of 70$ trichloroacetic
acid. After an overnight diffusion at room temperature, the amount of
acetaldehyde bound to the semicarbazide is determined by the method of
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Gupta and Robinson . A 0.2ml aliquot of the acetaldehyde-semicarbazone♦
complex in the side arm is diluted to 1 .0ml with water, and its optical 
density is read at 224nra against ,a blank cell. A reaction blank is prepared 
from the assay system ^escribed above except that 0.5ml of water is
added instead of the microsome suspension. An aliquot (0.2ml) of the 
solution in the side arm of this reaction blank is diluted to 1 ,0ml 
with water, and this is used for the blank cell.
Calculation. .
Under the condition of the assay, 0.1 ^ mole of acetaldehyde produced 
gives an optical density of 0.33.
* Optical density reading is equivalent to A X 0.1 yrnoles/l0min/3mg protein
• 0.33
where A = optical density reading
0.33
A X 0.1^pmoles/l0min/3mg protein = 0.A nmoles /min/mg protein
30
= 1000 X 0.A nmoles/min/mg protein 
30
= A X 10 nmoles/min/mg protein
1 ^
optical density reading X 10 = nmoles acetaldehyde produced/min/
• 0.99 mg microsomal protein
NADPH Oxidase Assay
NADPH oxidase activity was measured spectrophotometrically in
microsomal preparations by determining the rate of disappearance of
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NADPH at 340nm, as described by Gillette et al .
Assay
Experimental Cell Blank Cell
0.5ml phosphate buffer (0.2Mj pH7.4) 0.5ml phosphate buffer
0.3ml microsome suspension (Smg protein/ml) 0.3ml microsome; suspension
1 .0ml nicotinamide (100 pimoles) 1 .0ml nicotinamide
0 .2ml HgO 1.2ml H O
The reaction is started by adding 1.0ml NADPH (0.25 punoles) to the 
experimental cell, which is read at 340nm against the blank cell for 5 
minutes at 25°C using a Unicam SP 8000 split beam recording spectrophotometer. 
The change in optical density/minute is used to calculate the activity of 
NADPH oxidase; -- ' ' ■ -
Calculation
- X ¥ X .10 _ ^ ---- 1----   _ j^Q^gg NADPH oxidised/minute/
€ L v A d mg protem/ml microsomal protein
where
AE/min = change in optical density/minute
7 = total volume of cell = 3.0ml
c - molar extinction coefficient - 6.22cm^/umole NADPH at 340nm
d = light path = 1cm
v = volume of microsome suspension taken = 0.3ml
Catalase activity of human liver supernatant, and guinea pig
microsomal preparations was measured by the oxygen electrode method of 
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Goldstein . The advantage of this method is that linear reaction rates 
can be obtained, as the reaction is only measured for 30 seconds and a 
negligible proportion of the substrate is used up. Perborate which 
furnishes solu^i°n is used as the substrate for catalase.
Method
Oxygen saturated distilled water (3.0ml) is added to the reaction 
chamber of the oxygen electrode which is maintained at 30°C. The chart * 
recorder attached to the electrode is adjusted to give a 100$ full scale 
reading for oxygen saturated distilled water. The distilled water is
removed and 3.0ml of 0.033M sodium perborate in 0.05M sodium phosphate
buffer pH7.0 is added to the reaction chamber. The perborate is 
equilibrated to 30°C, lOpl of enzyme preparation is added to the reaction 
chamber, and the reaction is measured for 30 seconds. The oxygen 
concentration in the reaction chamber rises rapidly and at a constant rate 
for at least 30 seconds, before there is any decrease in the rate of 
production of oxygen. The specific activity of catalase is expressed as 
yimoles 0  ^evolved/minute/mg microsomal protein.
Calculation
Solubility of 0^ in water = 0.235 yimoles/ml at 30°C
= 0.705 jmnoles/3ml
100$ full scale reading = 100 units 5 0.705 ^ pmoles 0^
1 unit = 0.00705 ^ tmoles 0r>
If reaction rate = Aunits/30 seconds
= 2 Aunits/minute
then 2Aunits/minute = 2AX 0.00705 ymioles O^/minute
pnoles 09/min/mg protein = 2AX 0.00705
mg protein taken
Determination of Blood Ethanol by Gas-Liquid Chromatography
The internal standard gas-liquid chromatography (GLG) method of 
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Cooper was used. This method involves precipitating blood proteins 
before injection of the sample onto the GLG column. As propanol is used 
as sn internal standard, and the detector'response is the same for 
propanol and ethanol, accurate quantitation can be made (Fig 7). The 
method of Cooper was modified so that 20jj1 blood samples, obtained from 
the ear vein of guinea pigs, could be used.
Apparatus and Operating Conditions
A Pye 104 GLC instrument is used with a 5 foot glass column packed 
with Porapak Q (80-100 mesh). The instrument is equiped with a flame 
ionisation detector. Column temperature 170°C; injection port temperature 
200°C; carrier gas (nitrogen) flow rate 60ml/min; hydrogen flow rats 66ml/ 
rain and air flow rate 500ml/min.
Method
The ear vein is pricked with a fine needle and 20pl of blood is 
removed with a pipette which has been previously rinsed in heparin. The 
blood sample is added to 0.5ml of aqueous propanol (lOmg/lOOml) and the 
pipette is rinsed with the propanol to remove all traces of blood. 0.05ml 
sodium tungs.tate (lOg/lOOml) followed by 0.05ml of f-N sulphuric acid are 
added to the propanol to precipitate the blood proteins. The sample is 
centrifuged at 900g for 10 minutes to remove the precipitate, and 5pl of 
the supernatant is injected onto the GLC column for blood ethanol 
determination. A typical GLC trace obtained is illustrated in Fig 8.
Peak areas are measured by multiplying the peak height by its width at 
half height. .As the detector response is the same for ethanol and 
propanol, the following calculation holds:
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FIG* 7 GLC detector response to propanol and ethanol
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A typical GLC trace of blood ethanol estimation.
Propanol standard = IQmg/lGOnl = 0.05ng/0. 5ral
• • GLC sample contains O.OSmg propanol
when area of ethanol, peak is equal to area of propanol peak 
GLC sample contains O.OSmg ethanol
this 0.05mg>originally in 0.02ml blood 
5mg originally in 2ml blood 
250mg originally in 100ml blood 
### blood ethanol concentration = 250mg/l00rnl blood 
For unknown sample
Area ethanol^peak ^ _ ^ 00(j ethanol concentration in mg
A ea px pan p a ethanol/lOOral blood
Ethanol Clearance from the Blood
The rate of ethanol elimination from the blood, the amount of ethanol 
metabolized/Kg body weight/hour, CQ (theoretical ethanol concentration at 
zero time, assuming complete absorption and uniform distribution), and r 
(fraction of body*mass in which ethanol is equilibrated with the blood,)
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were determined by the method of Widmark as described by Khanna and Kalant 
The rate of clearance of blood ethanol is obtained by plotting a 
graph of blood ethanol concentration against time (Fig 9). A straight 
line is constructed from the linear portion of this graph using the method 
of least squares. The slope of this straight line is equal to the rate 
of ethanol clearance from the blood, which is expressed in mg ethanol/LOOml 
blood/hour.
Values for Gq are obtained by extrapolating the straight line graph to 
zero time, CQ is expressed in mg ethanol/lOOml blood, 
r is equal to:
— —^  = . rag______  _ litre/Kg
CGP mg/litre X Kg
v^ here A = total dose of ethanol in mg
CQ= ethanol concentration at zero time mg/litre blood 
P = weight of animal in Kg 
The amount of ethanol metabolized mg ethanol/Kg body weight/hour is 
calculated:
mg ethanol eliminated/litre blood/hour X r
~ 7TI— ^5 f  X = mg ethanol/Kg body weight/hour
litre X hour Kg
mg
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Blood ethanol clearance against time. C is& o
theoretical ethanol concentration at zero time, 
assuming complete absorption and uniform distribution.
Serum t^  of Diphenylhydantoin in the Guinea Pig 
 2 —
Animal treatment
Guinea pigs were fasted overnight and injected i.p. with 
diphenylhydantoin (25 mg/Kg). KLood samples were removed from the 
ear vein at 1, 2, 4, 6 and 24 hours after the injection. Serum was 
prepared in the normal manner and was used in the following 
radioimmunoassay for diphenylhydantoin estimation.
Radioimmunoassay of Diphenylhydantoin
97The conventional radioimmunoassay procedure of Paxton was
followed. Standard displacement curves were produced by addition of
increasing amounts of diphenylhydantoin to tubes containing trace 
3
amounts of H- diphenylhydantoin and antiserum in phosphate buffer. 
Separation of bound and free label was achieved by addition of a 
donkey anti - rabbit precipitating serum. After incubation for 1 hr 
at 57°G the tubes were centrifuged and the supernatant containing the 
free label was removed for counting in a liquid scintillation 
spectrometer. The guinea pig serum was diluted 1 in 100 and was
3
added to tubes containing trace amounts of H - diphenylhydantoin and 
antiserum in phosphate buffer. The tubes were then treated as above, 
and the concentration of diphenylhydantoin in the serum was obtained 
from the standard displacement curve. All determinations were carried 
out in duplicate. The concentration of diphenylhydantoin in guinea 
pig serum was expressed in^pg/ml. 
ii of Diphenylhydantoin , *
The concentration of diphenylhydantoin in guinea pig serum was 
plotted on semilog graph paper against time. The ti was calculated 
from the linear portion of the graph.
Human ADH Assay
Preparation of Supernatant
All procedures are carried out at 4°G. The liver biopsy sample is
homogenised in 0.25M sucrose containing Triton X-100, this has been shown
86previously by Raiha and Koskinen to give maximal ADH activities, A 
dilution of approximately 1 part tissue to 50 parts homogenising medium is 
used for both needle biopsy tissue and wedge biopsy tissue from surgery.
The homogenate is centrifuged at 10,000g for 30 minutes, and the resulting 
supernatant fluid is used for the determination of ADH activity, as well 
as catalase and NADPH dependent ethanol oxidizing system activities.
ADH Determination
18
The method of Von Wartburg et al was used as this can detect the 
presence of atypical ADH in biopsy samples by comparing the activity at 
pH8.8 with that at pHll.O. A modification of this method was carried out 
so that the final concentrations of NAD and ethanol were 0.5mM and ICOmM 
respectively. These concentrations gave maximum and linear reaction 
rates for the time interval of the reaction with ethanol (3 minutes) and 
the concentration of enzyme preparation used.
Assay
pH 8.8 pH ll.Q
1.4ml sodium pyrophosphate buffer 1.4ml glycine-NaOH buffer
(0.033M; pH 8.8) (0.033M;pH 11.0)
0.05ml NAD 0.05ml MAD
(final concentration 0.5mM) (final concentration 0.5ml-!)
0.05ml supernatant 0.05ml supernatant
The increase in optical density o£ each cell is recorded at 3A0nra on a
Unicam SP 8000 spectrophotometer for 5 minutes, at 25°C against air. 0.0cml
of ethanol (final concentration ICOmM) is then added to both cells and
the increase in optical density is recorded for a further 3 minutes. As 
each cell acts as its own blank, the optical density change/minute without 
ethanol is subtracted from the optical density change/minute with ethanol. 
The specific activity of ADH is calculated as described for guinea pig 
ADH. The activity of ADH at pH 3.8 and pH 11.0 is expressed as units/ 
g protein or units/g wet weight liver. One enzyme unit is equal to 
1 yoiols of NADH produced per minute at 25°C.
NADPH Dependent Ethanol Oxidizing System 
Activity in Human Liver
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The method of Mezey and Tobon was used, with the following 
modifications (a) 0.1ml of supernatant was added to the incubation 
mixture in a Thunberg tube to give a total assay volume of 1.0ml (b) 0.6ml 
of semicarbazide was added to the side arm of the Thunberg tube.
Principle
Acetaldehyde produced from ethanol by the enzyme reaction is trapped 
by semicarbazide to form an acetaldehyde-semicarbazone derivative. The 
concentration of this derivative is determined spectrophotometrically, and 
the amount of acetaldehyde produced by the reaction can be calculated.
Assay
/
0.6ml phosphate buffer (0.1M; pH 7.4)
0.1ml supernatant
0.2ml NADPH generating system containing (final concentrations)
NADP 0.3mM 
MgClg 5.OmM 
Nicotinamide 5.OmM
Isocitrate dehydrogenase IpM unit equivalent to 0.05ml 
The assay is carried out in duplicate, in Thunberg tubes containing 0.6ml 
of 0.015M semicarbazide HC1 in 0.16M phosphate buffer pH 7.0 in their 
side arms. The tubes containing the above assay solutions are 
preincubated at 37°C for 5 minutes. 0.1ml ethanol (llSmM final concentration) 
is then added to the tubes, and the reaction is incubated for 10 minutes.
The reaction is stopped with C.5ml of 70% TCA, and the amount of 
acetaldehyde produced is determined using the same method as described for 
the MSGS system. A reaction blank containing all the assay solutions,
I
|
i
I
i
except that the supernatant is replaced with water, is also incubated.
The semicarbazide solution in the side arm of this reaction blank is used 
to prepare a blank cell. The activity of the NADPH dependent ethanol 
oxidizing system is expressed as 'nmoles acetaldehyde produced/minute/mg 
of protein and nmoles acetaldehyde produced/minute/g wet weight liver.
Determination of Leucocyte Ascorbic Acid
Leucocyte ascorbic acid (La A) was measured by the method of 
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Denson and Bowers 
Reagents
(1) Diluent tor blood
200ml physiological saline 
50ral 6$ dextran 
2.0ml 10$ sequestrene 
This is prepared in bulk and distributed in 12.5ml amounts
(2) Reagent
100 vols 2.2$ 2,4-dinitrophenylhydrazine in ION
5 vols 5$ thiourea
5 vols 0.6$ GuSO ,5H 0 
4 2
(3) 5$ TCA
(4) 65$ H SO - -
2 4-
Approximately 3ml of blood is added to 12.5ml of diluent. The 
diluted blood is allowed to stand for half an hour at room temperature to 
allow the red cells to sediment. The supernatant fluid containing the 
while cells and platelets is removed and mixed, and a 0.2ml aliquot is 
added to 0.8ml of white blood cell (VJ3C) diluting fuid and a white cell 
count is performed. 10ml of the leucocyte containing fluid is centrifuged 
at lOOOg for 15 minutes, and the supernatant is discarded. 1.3ml of 5$ TCA 
is added to the pellet of white cells and this is thoroughly homogenised. 
The homogenate is centrifuged and 1.0ml of the supernatant is added to 
0.3ml of reagent in a test tubs. The tubes are incubated for 4 hours at 
37°C, and allowed to cool in an ice bath. 1.5ml of 65$ is added and
the tubes allowed to stand for 30 minutes. The optical density is read
at 520n:n against a reagent blank. A graph prepared from ascorbic acid 
standards of 0.4, 0.8, 1*3, 4.0 and lOpg/ml of 5$ TCA treated as above, 
is prepared. The ascorbic acid content of the supernatant is read from
O
this graph, and is expressed as jag/10 WBC.
Calculation *
Q
jig ascorbic acid/ml supernatant X 1.3 X 10
No of WBC in ICml
= jig ascorbic acid/lO^ WBC
100 .
The method of Lowry et al was used
Solutions
A: 2% NaoC0., in 0.1IT NaOH *■
B: 2* Sodium tartrate
Cr 1% Copper sulphate
D: Folin-Ciocalteu reagent diluted lil with water.
To 100ml of solution A add 1ml of solution B and 1ml of solution G, 
this reagent must be renewed daily. To 5ml of this working solution add 
lml of a diluted protein sample containing 10-100pg of protein/ml. Mix 
well and allow to stand for 10 minutes at room temperature. Add 0.5ml of 
solution D and mix immediately. After 30 minutes read the optical density 
at 750nm against a water blank treated in the same way.
Bovine serum albumin (fraction V) standards diluted to contain 25,
50, 75 and lOOpg protein/ml are treated as above, and a standard graph of 
optical density against protein concentration is constructed (Fig 10).
The concentration of the protein samples can be read of the graph and 
multiplied by their dilution to obtain the protein concentration of the 
original sample.
0-3
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Fi g . 10 Protein standard graph
Statistical Methods
Results are calculated and expressed as means - standard deviation 
(S.D.), the standard deviation being calculated from the expression;
S.L. = t l x - x }2
n-1
where X is any of the values measured, X is the mean value, and n the 
number of observations.
The significance of results was calculated by Students t test using 
the formula:
t =  xr x2
‘4
S,1 + i 
n- n
where s is an estimate of the combined standard deviation of both 
groups calculated from;
s2 = S l x - x ^ 2 + E { x - x ? f
ni + n2 ~ 2
X1 and ><2 are means both groups and n^ and n^ the number 6f 
observations in each group.
In some of the human studies where a normal distribution was not 
assumed, the Mann-Whitney U test was used.
U = n ^  + ^  (i^  + 1)
2
or equivalently,
TJ = + n2 (n2 + 1)
- R,2 2
where R^ = sum of the ranks assigned to group whose sample size is
R2 = sum of the ranks assigned to group whose sample size is n2
The method of least-squares was used to obtain the regression
coefficient of lines, and from this the correlation coefficient r.
With n pairs of associated observations represented b;y 
the true regression line for the regression of y on x is: 
y = a + /3x
the estimate of the true regression coefficient /3 is: 
t =. £{x-x} jy-y }
E M 2
Similarly, the true regression line for the regression of 3 
x = a' + 0y
and the estimate of the true regression coefficient is:
b" = £ { * - x } { y - y }
£ b - y f 2
The correlation coefficient r = Vbb"
(x, y),
on y is:
CHAPTER 1. 
ANIMAL EXPERIMENTS.
SECTION 1. 
PRELIMINARY CONSIDERATIONS.
Animal of Choice
In the field of alcohol research animal experimental models must 
he made, as far as possible, applicable to man, if an understanding 
and possible solution of an entirely human problem is to be achieved.
Any attempt to extrapolate results obtained from ethanol metabolism 
experiments on animals, and apply them to man, has inherent difficulties 
due to species differences. These differences can be minimised by 
choosing an animal that is as similar as possible to man, with respect 
to tolerance and metabolic handling of ethanol.
The rat has been extensively used for experimental studies on
ethanol metabolism, but there are disadvantages in its use. The 
tolerance of the rat to ethanol is much greater than that of man, the 
lethal blood ethanol concentration in the rat^ being 900mg/l00ml, 
compared with 500mg/l00ml in man^. The rate of ethanol metabolism 
in the rat,^* judged by blood ethanol clearance rates, is 45rog ethanol/
100ml blood/hr, which is much greater than that of man^ **' (l5mg ethanol/
100ml blood/hr).
Although the guinea pig has been less widely studied than the rat,
in many ways it is a better choice of animal for studies on ethanol
metabolism. The lethal blood ethanol concentration of the guinea pig
is similar to that of man; an oral dose of 4g ethanol/Kg body wt results
in a lethal blood ethanol concentration of 500mg/l00ml in both man and 
4-5the guinea pig . In contrast, the rat requires an oral dose of 
approximately ethanol/Kg body wt to reach its lethal blood ethanol 
concentration of 900mg/l00ml^. Jervis‘S  found the blood ethanol 
clearance rate of guinea pigs to be 33nig/lOOml/hr. A further important 
similarity between the guinea pig and man is that both species are
unable to synthesise ascorbic acid.
Because of the above similarities between the guinea pig and man,
with respect to tolerance and metabolic handling of ethanol, and the
inability of both species to synthesise ascorbic acid, the guinea pig
was the animal of choice for the present studies.
Length of time on ascorbic acid deficient diet.
Guinea pigs fed an ascorbic acid deficient diet for 12-16 days
show no obvious signs of scurvy, but have increased plasma half lives
76
(tv) of a number of drugs • This is due to decreased microsomal drug
2
metabolizing enzyme activities and decreased concentrations of N
77 7ft 1
microsomal electron transport components 9 f . The ascorbic acid 
deficient guinea pig is therefore a useful animal model for studying 
the effects of decreases in the activity of the microsomal drug 
metabolizing system on ethanol metabolism. A preliminary experiment 
was therefore carried out to establish a dietary regimen, which would 
give similar results to those of the previous studies outlined above. 
The serum ti of diphenylhydantoin (DPH) was used to assess the extent 
of the decrease in microsomal drug metabolism.
Materials and Methods.
Twelve male albino Hartley strain guinea pigs (A. Tuck and Son 
Ltd., Rayleigh, Essex) weighing 200-250g were fed an ascorbic acid 
deficient diet for 14 days. The composition of the diet is given in 
the Methods section. This strain and weight of guinea pig was used 
in all the following animal experiments. Six guinea pigs were given 
a daily supplement of 50 mg ascorbic acid, dissolved in 1.0ml water, 
by gastric intubation. These ascorbic acid supplemented animals were 
the normal controls for the ascorbic acid deficient group.
Liver ascorbic acid concentration and serum ti of DPH were
t
measured in each animal. Hie details of these estimations are given
in the Methods section. The body weights of the animals were also
noted during the experiment.
Results.. .    . 1,, .  , , »
In fig 11, the mean body weights of the two groups of animals are 
plotted against time on the ascorbic acid deficient diet. There was no 
significant difference in the body weights of the two groups of animals 
over the period of the experiment.- The concentration of liver ascorbic 
acid and the serum t^ of DPH are given in table 1, for both groups of 
animals. .The liver ascorbic acid concentration of the ascorbic acid 
deficient group was significantly lower (P< O.OOl) than that of the 
normal animals, and this represented a reduction to 28 per cent of the 
concentration found in the normal animals. The serum t^ of DPH was 
significantly increased (P< 0.005) from 5*5 - 0.75 brs in the normal 
animals to 7*5 - 0.92 hrs in the ascorbic acid deficient animals. This 
represents an increase of approximately 36 per cent in the serum t^ of 
DPH in the ascorbic acid deficient animals compared with that found in 
the normal animals.
There were no signs of scurvy in the ascorbic acid deficient animals 
after 14 days on the ascorbic acid deficient diet.
Discussion.
The increase in serum of DPH found in the present study is in
a
76agreement with the results obtained by Axelrod et al , who demonstrated 
increases in plasma t^ of acetanilide, aniline and antipyrine in guinea 
pigs of similar weight (260-280g), maintained on an ascorbic acid 
deficient diet for a similar time period (16 days).
Weight (g)
250
 ASCORBIC ACID DEFICIENT
 NORMAL
14 Days
Fi g . I I
Body weight changes with time in normal and ascorbic 
acid deficient guinea pigs.
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Several species, including man^^ and the rat^^, metabolize DPH
mainly by ring hydroxylation in the pa.ra position to 5-P“OH-phenyl-5-“
phenylhydantoin. The serum tx of 5*5 hrs found in the normal guinea
2
106pigs in the present study compares with tha.t of 10 hrs found in man
The increase in serum t^ of DPH in the ascorbic acid deficient guinea
pigs probably reffects a decrease in the activities of the microsomal
hydroxylase enzymes responsible for its ring hydroxylation, as has
77 78 103
been previously shown for other drugs by several workers ’
107Kuether et al found the concentration of liver ascorbic acid
in guinea pigs fed a normal chow diet supplemented daily with cabbage
to be 260 pg/g wet wt, which is the same as that found in the livers of
108species like the rat and mouse which are able to synthesise ascorbic
acid. This concentration must therefore represent total tissue saturation
of ascorbic acid. The liver ascorbic acid concentration of 170 pg/g wet
wt obtained in the present study compares favourably with the concentration
of 190 pg/g wet wt found by Zannom et al*'^ in animals of the same weight
receiving the same daily supplement of ascorbic acid. • It is difficult
to achieve,complete saturation of ascorbic acid in guinea pig liver
110
with daily oral supplements. Sato and Zannoni found that even 75 mg/day
of ascorbic acid given orally was not sufficient to saturate the livers
of weanling guinea pigs. The problem of increasing the gastrointestinal
absorption of ascorbic acid can be overcome by giving intramuscular
injections of the vitamin, but this in turn can lead to stress effects
81and can actually lower the tissue ascorbic acid concentration 
Supplementing the normal animals’ diet with cabbage leads to tissue 
saturation, but this would introduce other dietary differences between 
the normal and ascorbic acid deficient animals. It was therefore 
accepted that the guinea pigs used in the present study were not 
completely saturated with ascorbic acid.
As the 14 day dietary regimen used was sufficient to bring about
changes in microsomal drug metabolizing enzyme activities, as judged 
by the increase in serum of DPH, it was decided to adhere to the 
above dietary conditions for all further experiments involving ascorbic 
acid deficient guinea pigs.
SUCTION 2 
REDOX STATS CHANGES WITH ETHANOL.
The redox state of the various subcellular compartments of the 
liver is shifted to a more reduced level during ethanol metabolism, 
due to the increased production of NADH by ADH and other NAD dependent
dehydrogenases involved in ethanol metabolism * This shift in
* 111 hepatic redox state can influence both the metabolism of ethanol , and
112 115the biochemical changes resulting from its metabolism * .
One example of the latter effect is ethanol induced impairment of 
112 113
the TCA cycle flux *  ^which is thought to be due to the increase
,* 112 
in the cytoplasmic and intramitochondrial HADE/NAD ratios* Lindros
using perfused liver from normal, hypothyroid and hyperthyroid rats,
showed that there was a good correlation between the extent of the
redox state shift with ethanol, and the degree of impairment of the
TCA cycle flux.
The dissociation of the ADH—NADH complex is considered the slowest
Q
step in the ADH reaction , consequently the redox state, and in
particular the concentration of free NADH in the cytoplasm, will
affect this dissociation and contribute to the control of the ADH
reaction. Decreases in the activity of ADH can also affect ethanol
oxidation, as Papenberg'*'^ has shown that the administration of pyrazole,
which inhibits ADH activity, lowers the rate of elimination of ethanol
in perfused rat liver* In animals with normal or raised ADH activities
however, it is the hepatic redox state that is the major regulatory
115mechanism of ethanol oxidation- .
Previous studies on redox state changes after ethanol administration
55 111—113 115have been mainly acute studies carried out on rats * * Only
116 117
two studies have been carried out on chronic ethanol treated rats * *
As far as can be established, no previous work has been carried out on
the in vivo effect of ethanol on the hepatic redox state of the 
guinea pig* It was therefore decided to investigate the effects of 
both acute and chronic ethanol administration on the hepatic redox
state of normal and ascorbic acid deficient guinea pigs* Starvation,
* 87
which alters the hepatic redox state of rats , was also studied in
guinea pigs•
Materials and Methods
Redox state changes after ethanol administration to starved guinea nigs*
Twelve male albino guinea pigs, weighing 200-25Og, were starved 
for 72hr* During this time they were allowed access to water and 
received 50mg ascorbic acid daily by gastric intubation. At the end of 
this 72 hr period, six animals were injected i.p. with 1.5g ethanol/Kg 
body wt as a 30% (W/Y) solution in isotonic saline* The remaining six 
animals acted as controls and received the same volume of isotonic 
saline* After 30 min the animals were killed by cervical dislocation 
and their livers rapidly removed and freeze clamped. Metabolites were 
extracted and measured as described previously in the Methods section. 
Redox state changes after ethanol administration to chronic ethanol 
treated normal and ascorbic acid deficient guinea pigs.
Male albino guinea pigs, weighing 200-250g, were fed the ascorbic 
acid deficient diet, described previously in the Methods section, for 
14 days. The ethanol pretreated groups were intubated daily with 2.5g 
ethanol/Kg body wt as a 50% (W/V) solution in water. Control groups 
received isocaloric quantities of glucose* Half the ethanol and glucose 
groups received a daily supplement of 50mg ascorbic acid, dissolved in 
their respective intubation solutions* These animals were the normal 
controls for the ascorbic acid deficient groups* The animals were
fasted overnight (18 hr) on the 14th day and injected i.p with 1.5g 
ethanol/Kg body wt as a 30% (W/V) solution in isotonic saline. Control 
animals received the same volume of isotonic saline. After 30 min 
the animals were killed by cervical dislocation and their livers 
rapidly removed apd freeze clamped, metabolites were extracted and 
measured as previously described in the Methods section.
Results.
The cytoplasmic redox state of the starved animals, expressed as 
the calculated free NADH/MD+ ratio (table 2) is in a more reduced 
state than that of the normal and ascorbic acid deficient animals 
fasted 18 hr (table 3)* Conversely, the intramitochondrial redox 
state of the starved animals (table 2) is in a more oxidised state than 
that of the normal and ascorbic acid deficient animals (table 4).
These differences in redox states can be related to differences in 
the concentration of the metabolites used to calculate them. The 
lactate and pyruvate concentrations of the starved animals are lower 
than those of the normal and ascorbic acid deficient animals, whereas 
the 3-QH-butyrate and. acetoacetate concentrations are much higher in 
the starved animals. After ethanol injection the cytoplasmic and 
intramitochondrial redox states of the starved animals are similar to 
those of the ethanol injected normal and ascorbic acid deficient 
animals. The weight of the starved animals was reduced by 28% at the 
end of the 72 hr period of starvation.
The well documented cytoplasmic redox state shift after ethanol 
administration is demonstrated in table 3* f°r all normal and 
ascorbic acid deficient groups injected with ethanol, compared with 
their saline injected controls. There is a significant (P<0 .02)
’T'n'n"t o p CTrtoasmic and Antra^i i ^ o hondrial 
redox state chan.ee 3 with ethanol 
in starved guinea pigs.
A
St amred .Starved + e thane1
lactate 535
j.
67 1036
+
123
Py.ruvate 21
.1.
3 26
+
4
Lac tate/pyruvate 26.8 + 1-7 38.8
+ 2.1
Cytoplasmic * . t
free TTADH/ITAD+X 10 30.1 T 1.9 44.3
+ 2.6
3-Hydroxybutyrate 149
f 10 252 + 22
Acetoacetate 259
+ 18 190 + 15
3-Hydroxybutyrate/acetoacetate 0.59 0.12 1.34
+
0.15
Intramitochondrial ** +free NADH/lTAI)‘ X 10" 2.89
+ 0.53 6.52 0.71
* Calculated from the lactate/pvruvate ratio of each animal using 
the value of l.'ll X 10~4 for the equilibrium constant of lactate
dehydrogenase.87
** Calculated from the 3-hydroxybutyrate/acetoacetate ratio of each 
animal using the value of 4.93 X 10“ 2 for the equilibrium constant 
of 3-hydroxybutyrate dehydrogenase.®7
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decrease in the extent of the redox state shift after ethanol in
both the normal and ascorbic acid deficient chronic ethanol treated
guinea pigs, compared with their respective unpretreated controls.
This is also apparent in table 4 for the intramitochondrial redox 
*
state changes after ethanol administration. Again the chronic ethanol 
treated animals show a significant decrease (P<0,01) in the extent of 
their redox state shift after ethanol administration, compared with 
their unpretreated controls. No statistical difference can be seen 
between the redox states of the ascorbic acid deficient groups and 
their normal controls.
Discussion.
The possibility' of starvation affecting the ascorbic acid 
deficient guinea pigs can be eliminated, as their metabolite 
concentrations are similar to those of the normal animals, and both
groups have very different metabolite concentrations from those of the
87
starved animals. Williamson et al have shown tnat 48 hr starvation
in the rat produces a parallel shift in the cytoplasmic and
intramitochondrial redox state to a more reduced state. The 72 hr
starved guinea pigs used in the present work showed similar changes to
87
those demonstrated by Williamson et al , in that their cytoplasmic 
redox state was in a more reduced state than that of tne 18'hr fasted 
guinea pigs, but their intramitochondrial redox state was shifted to a 
more oxidised state. It is possible that the length of time of 
starvation has produced a severe state of ketosis, as shown by the 
large increases in the ketone bodies acetoacetate and 3-OH-butyrate, 
and that this is affecting the equilibrium of the intramitochondrial 
redox state pairs. This may explain the non-parallel changes in redox
state in the cytoplasmic and. intramitochondrial compartments of the
starved guinea pig. After ethanol administration there is a shift to
a more reduced redox state in "both compartments, which indicates that
the starved guinea pig can still respond metabolically to ethanol, as
55Smith and Newman have shown for starved rats .
113Lindros and Hillbom have shown that there ere parallel changes
to a more reduced state, in the lactate/pyruvate and 3-OH-butyrate/
acetoacetate ratios after ethanol administration to normal fed rats.
This has also been demonstrated in the present work for the normal
and ascorbic acid deficient groups injected with ethanol.
The decrease in the extent of the redox state shift after ethanol
injection in the chronic ethanol treated guinea pigs, compared with that
found in their respective unpretreated controls, is in agreement with
117results obtained by Domschke et al . These workers demonstrated an
attenuation in the redox state shift after acute ethanol administration
to chronic ethanol treated rats, compared with the redox state shift
after acute ethanol administration to control animals, which had
previously been given isocaloric amounts of carbohydrate. The chronic
ethanol treated rats in this study received 13-15S ethanol/Kg body wt/
day as part of a liquid diet over 25 days. This is a much larger
dose given over a longer period of time, than that producing similar
results in the guinea pigs of the present study.
116The results of Gordon , who also studied chronic ethanol treatment
in rats receiving ethanol as part of a liquid diet, are difficult to
117relate to those of Domschke et al and the present study, as no 
acute ethanol treated control animals were studied. Gordon"*^ 
demonstrated that the 3-OE-butyrate/acetoacetate ratio of chronic-
77
ethanol treated rats was in a. more reduced state than that of control 
animals who had received no ethanol. There was no increase in the 
lactate/pyruvate ratio of the chronic ethanol treated rats. As details 
of the blood ethanol concentration and amount of ethanol ingested prior 
to sacrifice were not given for these animals, it is difficult to assess 
the actual contribution of ethanol intake to these results.
In the present study, the decrease in the extent of the redox state 
shift with ethanol in the chronic ethanol treated guinea pig, cannot 
be due to differences in blood ethanol concentration between the acute 
and chronic ethanol treated guinea pigs. The theoretical zero time 
concentration of ethanol in the blood is the same for both groups (table 7)»
The decrease in the extent of the redox state shift after ethanol
administration to the chronic ethanol treated guinea pig may represent
53metabolic adaptation to ethanol. Rawat and Kuriyama have previously
shown that chronic- ethanol treated mice have an increased mitochondrial
31permeability to NADH. Videla et al have also demonstrated that 
chronic ethanol treatment in rats results in a faster mitochondrial 
oxygen consumption, which suggests that these mitochondria can reoxidise 
NADH at a fan ter rate. It is uncertain which adaptive mechanism may 
be operating in the chronic ethanol treated guinea pigs of the present 
study.
115Hillbom has previously demonstrated the importance of the redox 
state in. the regulation of ethanol elimination in vivo. An increase in 
ethanol elimination of 20 mg/kg body wt/hr was obtained in rats treated 
with promethazine, which decreased the extent of the redox state shift 
with ethanol by 50 per cent of that' of untreated control animals. The 
10 per cent decrease in the extent of the redox state shift after ethanol 
administration, found in the chronic ethanol treated guinea pigs in the 
present work, is probably too small to affect the rate of ethanol
elimination. This is substantiated in table 7, £.s there is no differenc 
in the rate of ethanol elimination from the blood between the chronic 
ethanol treated guinea pigs and their untreated controls.
SECTION 3*
Ethanol Metabolism in the Ascorbic 
Acid Deficient Guinea Pig*
Possible in vitro mechanisms of the microsomal ethanol oxidising 
system (MEOS) have been described previously. MEOS has been shown in
34vitro to be similar to the hepatic microsomal drug metabolizing system. ,
as it can oxidize ethanol to acetaldehyde in the presence of NADPH and
Op* The nature of MEOS activity has been' widely studied using inhibitors
to differentiate between the various possible enzyme reactions
involved^,^ ,^ ,^ ^ # Unfortunately the various enzyme inhibitors used
are not entirely specific, and some doubt as to the exact mechanism of
MEOS activity still remains.
The in vivo significance of MEOS has also been widely studied using
inhibitors of the microsomal drug metabolizing system, in an attempt to
establish the extent of microsomal involvement in ethanol metabolism.
These agents are again not entirely specific and results obtained are
inconclusive. The injection of SKE 525-A, which is a microsomal enzyme
inhibitor, had no effect on the rate of ethanol clearance from the blood
120of rats or the whole body of mice , indicating that ethanol is not
metabolized by micros canal enzymes to any significant extent.
Unfortunately SKF 525-A also caused a delay in the absorption of 
120ethanol in the rat , and results obtained with this compound are
therefore questionable.
The guinea pig is a useful animal model for studies on the
significance of MEOS in vivo, as the plasma half-life of a number of
76
drugs is increased in the ascorbic acid deficient animal • This is 
due to decreased microsomal drug metabolizing enzyme activities, and 
decreased amounts of microsomal electron transport components^^,^ ^ ,^ ^. 
Phenobarbitone pretreatment returns these decreased microsomal enzyme 
activities to normal, indicating that the microsomal enzyme protein
synthesising mechanism is operable in ascorbic acid deficient guinea
. 109pigs '.
In the present study non-specific effects introduced by microsomal 
enzyme inhibitors were avoided by the use of the ascorbic acid deficient 
guinea pig as an animal model, Experiments were carried out to assess 
the effect of ascorbic acid deficiency and chronic ethanol treatment on 
ADH activity, The effect of decreased microsomal electron transport 
components and decreased microsomal enzyme activities on the rate of 
ethanol elimination in vivo, and the ability of ethanol to induce 
microsomal enzyme activities was also investigated.
METHODS
Animal Treatment
Male albino guinea pigs, weighing 200-250g were fed the ascorbic 
acid deficient diet described previously, for 14 days. The ethanol 
pretreated groups were intubated daily with 2.5g ethanol/Xg body 
weight as a 50% (W/V) solution. Control groups received isocaloric 
quantities of glucose. Half the ethanol and glucose groups received a 
daily supplement of 50mg of ascorbic acid dissolved in their respective 
intubation solutions. These animals were the normal controls for the 
ascorbic acid deficient groups.
Ethanol metabolism in vivo.
The animals were fasted overnight (18 hr) on the 14th day and 
injected i.p. with 1.5g ethanol/Kg body weight as a 50% (W/V) solution 
in isotonic saline. Blood samples were removed from the ear vein at 
half-hour intervals for 5 and blood ethanol concentrations and 
rates of ethanol metabolism were measured as described previously.
Preparation of guinea pig liver microsomes
Animals were treated as above for 14 days but received no ethanol 
for 24 hr prior to sacrifice. Microsomes were prepared as described 
previously.
Peterminations. *
Aniline hydroxylase, cytochrome P-450, cytochrome b^ , MEOS, NADPH 
oxidase, catalase, ADH, liver ascorbic acid and protein were measured 
as described previously.
Results.
No difference in terminal body weight, liver weight, liver/body 
weight or ADH activity was found between any of the groups of animals 
studied (Table 5)* ike liver ascorbic acid concentration was decreased 
to 30 per cent of normal values in both the ascorbic acid deficient 
(scorbutic), and chronic ethanol treated ascorbic acid deficient groups. 
This did not produce any changes in the other parameters measured in 
Table 5*
Microsomal protein content, aniline hydroxylase and NADPH oxidase 
activities were significantly decreased in the ascorbic acid deficient 
groups, compared with their normal controls, although catalase and 
MEOS activities were unchanged (Table 6). Cytochrome P-450 
concentration was significantly decreased in the ascorbic acid deficient 
animals, but no change in the concentration of cytochrome b^ was noted. 
No evidence of microsomal enzyme induction was found in any of the 
ethanol pretreated groups.
Pretreatment of guinea pigs with 2.5g ethanol/Kg body weight/day 
for 14 days had no effect on the rate of clearance of ethanol, from the 
blood, or calculated rate of ethanol metabolism (Table 7)* Ascorbic 
acid deficiency also had no effect on the rate of ethanol metabolism
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in vivo, in guinea pigs fed an ascorbic acid deficient diet for 14 days* 
Discussion
As far as can be established, the only previous study on ethanol
102
metabolism in ascbrbic acid deficient guinea pigs is that of Jervis ,
who showed that ascorbic acid deficient guinea pigs had a decreased
rate of clearance of ethanol from their blood* In this study only one
ascorbic acid deficient and one control animal was studied and no
statistical interpretation of the results was therefore possible* The
ascorbic acid deficient animal was studied alter 4 weeks on an
ascorbic acid deficient diet, which resulted in loss of weight and
haemorrhage of joints, and it is likely that starvation caused the
decrease in the rate of ethanol clearance from the blood of this animal* 
55Smith and Hewman have demonstrated that starvation leads to impaired
ethanol metabolism in the rat. A further objection to the methods used
102in the study of Jervis , is that blood samples were obtained by
multiple cardiac puncture which can lead to pericardial haemorrhage and
102affect the results obtained. Unfortunately Jervis did not measure 
any of the enzymes involved in ethanol metabolism in these guinea pig3.
In the present study the lack of effect of chronic ethanol treatment 
on the activity of guinea pig ADH is in agreement with the results of 
other workers, who failed to show any induction of ADH activity in 
chronic ethanol treated rats.^,^ ^ ,‘^ ^*
The decrease in aniline hydroxylase activity in the ascorbic acid
103deficient guinea pigs is in agreement with results of Kato and 
123Wade et al, who studied guinea pigs fed an ascorbic acid deficient diet
123
for 12 days. Wade et al also showed a decrease in the concentration 
of cytochrome P-450 and microsomal protein, but no change in the
concentration of cytochrome b in these animals, which is in agreement
0
with results obtained in the present study.
Previous workers have demonstrated that chronic ethanol treatment
of rats leads to induction of microsomal enzyme activities'^* and
122increased concentrations of cytochrome P-450 • These rats were fed
31 12212-14g ethanol/% body weight/day in a semi-liquid diet for 14 days, *
which also resulted in an increased rate of ethanol elimination from
the blood. Induction of microsomal systems depends on the quantity
of ethanol and its mode of administration. In the present study 2.5#
ethanol/Kg body weight was given as a single daily oral dose for 14 day3,
and this could not be raised as the ID,-, for a single oral dose of
30
ethanol is 4o/% body weight in guinea pigs^.
In contrast to the present study, several workers have previously
shown that NADPH oxidase activity is increased in chronic ethanol 
30 31 39treated rats, * * again the amount of ethanol and its mode of
administration may contribute to the difference in these results. MEOS
activity is also increased after chronic ethanol treatment in rats,^*^*^^
31while catalase activity is unaltered . It has been suggested by
30Carter and Isselbacher that the increase in MEOS activity is due to 
the increase in NADPH oxidase activity in chronic ethanol treated rats.
These authors consider MEOS activity to be a product of NADPH oxidase 
and catalase activity.
If MEOS activity is a product of NADPH oxidase and catalase 
activity, the decrease in NADPH oxidase activity found in the ascorbic 
acid deficient guinea pig should result in a decrease in MEOS activity, 
as NADPH oxidase and its production of 2^0^ is considered the rate 
limiting step in this system^ It is possible that NADPH oxidase
activity is not sufficiently reduced in the ascorbic acid deficient 
guinea pig to bring about a reduction in MEOS activity.
Erom the results of the present study It is not possible to 
establish the precise involvement' of NADPH oxidase and catalase in 
MEOS activity, but it is obvious that MEOS activity is not related to 
tne activity of the microsomal drug metabolizing system. The 
concentration of cytochrome P-450 was decreased in the ascorbic acid 
deficient guinea pig, resulting in a decrease in the activity of 
aniline hydroxylase,a ‘true* microsomal drug metabolizing enzyme, 
whereas MEOS activity was unchanged and did not appear to be dependent 
on the concentration of cytochrome P-450.
This is in agreement with more recent in vitro studies of Vatsis
125
et al , who showed that preincubation of mouse liver microsomes with 
NADPH resulted in peroxidation of unsaturated fatty acids of the 
microsomal phospholipids. This resulted in a destruction of cytochrome 
P-450 and decreased activities of aniline hydroxylase, although no 
change in the activities of MEOS or NADPH oxidase were evident.
Ihe3e authors also concluded that cytochrome P-450 was not involved in 
MEOS activity.
In conclusion, no evidence bas been found for microsomal involvement
in MEOS activity in vitro, or ethanol metabolism in vivo; as a reduction
in microsomal drug metabolizing enzyme activities and decreased
cytochrome P-450 concentrations, had no effect on MEOS activity or
ethanol elimination from the blood. Drugs that are substantially
metabolized by the microsomal drug metabolizing system have increased
76
plasma half-lives in ascorbic acid deficient guinea pigs, but no 
decrease in the rate of elimination of ethanol from the blood was
observed in the ascorbic acid deficient guinea pigs used in the 
present study. When ADH activity is normal no further systems appear 
to be required for ethanol metabolism. This is in agreement with 
previous studies on the significance of MEOS in vivo, except in the 
present work non-specific effects of inhibitors of microsomal drug 
metabolizing enzymes have been avoided.
SECTION 4.
ETHANOL METABOLISM IN THE PHENOBARBITONE 
TREATED GUINEA PIG.
As the effect of decreased microsomal enzyme activities on the
rate of ethanol metabolism was investigated in the previous section, it
was of interest to investigate the converse system wheie these enzymes
are increased in activity. '
Phenobarbitone is a powerful inducer of the microsomal drug 
126metabolizing system , and has been used previously for studies on
the effects of increased microsomal enzyme activities on ethanol
Metabolism.30*58’120'127*
Unfortunately there are disadvantages in the use of barbiturates
for studies on ethanol metabolism, as both phenobarbitone and barbitone
have been shown to inhibit ADH and prevent the redox state shift after
128 129ethanol administration. 9 T.he rate of ethanol oxidation in
129mouse liver slices is also decreased in the presence of barbitone.
130Kyogoku et al have demonstrated that barbiturates can bind to
adenine nucleotide derivatives, and it is probable that the ADH
reaction is inhibited by the binding of NAD+ to barbiturate.
127Khanna et al showed that 24 hours after the last dose of 
phenobarbitone, there is no inhibition of ethanol metabolism in rats.
If phenobarbitone is therefore allowed to clear from the body prior to 
investigations on ethanol metabolism, the effect of increased activities 
of microsomal drug metabolising enzymes can be studied, without 
complications arising from enzyme inhibition.
Methods.
Male albino guinea pigs weighing 200-250g were fed the ascorbic 
acid deficient diet, described previously, for 14 days. Control animals 
were intubated daily with 50mg ascorbic acid dissolved in 1ml water, 
and the ascorbic acid deficient animals were intubated, with the same 
volume of water.
Phenobarbitone (0.5mg/ml) was added to the drinking water of half 
the deficient and control animals on the morning of day 10 of the 
dietary period, and was removed on the morning of day 14* The 
phenobarbitone solution was made Up fresh each day and the animals 
drank between 30 dnd 50ml daily.
In vivo ethanol metabolism was measured, as described previously, 
after an overnight fast on the 14th day. Enzyme and ascorbic acid 
determinations were performed on animals treated as above for 14 days, 
except that they received no ethanol. 
lie suits.
The phenobarbitone treated animals had significantly increased 
liver and liver/body .weights compared with their untreated controls 
(P<0.00l). ADH activity was unchanged by phenobarbitone (Table 8).
The activity of aniline hydroxylase, and the concentrations of 
cytochrome P-450 and microsomal protein, wer0 significantly increased 
after phenobarbitone treatment in both the ascorbic acid deficient 
(scorbutic) and normal phenobarbitone treated animals (Table 9)•
KADPH oxidase, catalase and MEOS activities were unchanged, as was the 
concentration of cytochrome b^. Phenobarbitone pretreatment returned 
the activity of aniline hydroxylase and the concentration of cytochrome 
P-450, in the phenobarbitone treated ascorbic acid deficient guinea 
pig, to near normal values.
In agreement with results obtained in the previous section, 
significant differences were found between the ascorbic acid deficient 
and normal animals, with regard to aniline hydroxylase and NADPH oxidase 
activities, and the concentrations of cytochrome P-450 and microsomal 
protein.
Phenobarbitone pretreatment had no effect on the rate of ethanol
ab
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clearance from the blood or on the calculated rate of ethanol 
metabolism, in either the ascorbic acid deficient or normal 
phenobarbitone pretreated groups (Table 10)*
Discussion.
Guinea pig ADH was not affected by phenobarbitone when its activity
was measured 24 hours after phenobarbitone administration, which
suggests that phenobarbitone had been cleared from the body or was
present in insufficient quantities to interfere with the ADH reaction.
The increase in liver/body weight and microsomal protein in the
phenobarbitone treated guinea pigs is in agreement with results obtained
127with phenobarbitone treated rats •
109Zannoni et al have shown previously that phenobarbitone pretreatment
increased the cytochrome P-450 content of guinea pig microsomes and
increased the activity of aniline hydroxylase. These authors also
showed that, the decreased microsomal enzyme activities and decreased
concentration of cytochrome P-450 in the ascorbic acid deficient guinea
pig, could be returned to normal values after phenobarbitone pretreatment •
The microsomal enzyme protein synthesising mechanism is therefore
operable in ascorbic acid deficient guinea pigs. This has been
confirmed .in the present study.
127Khanna et al demonstrated an increase in MEOS after phenobarbitone
treatment in rats, the increased activity was significant whether it
was expressed per mg of microsomal protein or per g of liver. Lieber
and DeCarli^ and Mezey'*’^  demonstrated an increase in MEOS after
phenobarbitone, only when its activity was expressed per g of liver.
30Carter and Isselbacher failed to show any change in MEOS after 
phenobarbitone, when its activity was expressed per mg of microsomal 
protein. These authors also found that NADPH oxidase activity was
unchanged, by phenobarbitone treatment. The difference in these results
could be due to variations in the duration, dose and route of
administration of phenobarbitone between the studies. Although Khanna 
127
et al did obtain an increase in MEOS activity after phenobarbitone
treatment, there was no change in the rate of ethanol clearance from
the blood of rats used in their study. The lack of effect of
phenobarbitone on MEOS or NADPH oxidase activity in the guinea pigs
of the present study, agrees with the above results obtained by
30Carter and Isselbacher in rats.
In the present study aniline hydroxylase activity was increased by 
over 30 per cent, and cytochrome P-450 concentration was increased by 
over 60 per cent in the phenobarbitone treated guinea pigs, but MEOS 
activity and the rate of ethanol metabolism in vivo was unchanged. As 
MEOS activity is not induced by phenobarbitone, and is not dependent 
on the concentration of cytochrome P-450, it does not appear to have 
properties associated with ftruef microsomal enzymes.
No evidence has been found for an involvement of microsomal drug 
metabolizing enzymes in ethanol metabolism, as an increase in aniline 
hydroxylase activity and cytochrome P-450 concentration had no effect 
on ethanol metabolism in vivo.
CHAPTER 2. 
HUMAN STUDIES
SECTION 1.
HEPATIC ALCOECL DEHYDROGENASE ACTIVITY 
AND LEUCOCYTE ASCORBIC ACID CONCENTRATION.
SECTION 1 (i)
RELATIONSHIP IN PATIENTS VITH NON-ALCOHOLIC 
LIVER DISEASE.
Alcoholics suffer from many dietary deficiency states as their
dietary intake is usually inferior in quality and quantity to that of
132 133non-alcoholics. Studies by O'Keane et al have shown that
ascorbic acid deficiency associated with an inadequate intake is
common in alcoholics.
134.Leevy et al have also demonstrated that hypovitamino sis is
common in both alcoholic and non-alcoholic liver disease. This is due
to dietary intake being inadequate to meet increased requirements
imposed by tissue injury. Reduced levels of leucocyte ascorbic acid
135are frequently found in patients with liver disease.
Human alcohol dehydrogenase activity (ADH) is decreased in patients 
with histological evidence of liver disease.^^^,^ ^^,^ ^  ADH activity 
is lowest in subjects with cirrhosis, especially where jaundice is also 
present.
Because of the link between nutritional status and liver disease, 
it was of interest to investigate whether the extent of liver disease, 
as determined by histology, could be related to the degree of 
hypovitaminosis. As ascorbic acid has been measured previously in
guinea pigs, it was decided to measure this vitamin in humans, especially
133 135as it is reduced in alcoholics and patients with liver disease.
Leucocyte ascorbic acid (LAA) concentration has been shown by Krebs 
139et al ' to be the best indirect method of assessing tissue ascorbic 
acid concentration.
As ADH activity is decreased in liver disease,^6,137*138 
possibility of a relationship between ADH and LAA concentration was 
also investigated.
Methods.
Twelve patients with clinical or biochemical evidence of non-
alcoholic liver disease were studied. Liver tissue was obtained by 
Menghini needle biopsy with the informed consent of the patient. Half 
the biopsy was used for histological studies, and the other half for 
ADH determination. ADH activity and LAA concentration were measured 
as described previously. In addition liver function tests were performed, 
including serum aspartate and alanine transferase, bilirubin, 
alkaline phosphatase, and albumin and globulin levels.
Results.
In table 11, ADH activity, LAA content and the summary of the 
histological findings of the 12 patients are detailed. There was no 
obvious relationship between LAA concentration and histological findings, 
or between ADH activity and histology. Using the method of least 
squares, a highly significant linear correlation coefficient r=0.88 
(P< 0.001) was obtained when each patients ADH activity was plotted 
against its corresponding LAA concentration (fig. 12). No relationship 
was found between ADH activity and liver function tests.
Discussion
Although a highly significant correlation coefficient was 
obtained when ADH activity was plotted against LAA concentration, the 
nature of this relationship is unclear. ADH activity appears to be 
related to LAA concentration, but as this relationship was found in 
patients with liver disease, it is possible that it is simply a 
result of liver disease.
To establish the exact nature of this relationship, it would be of 
interest to see whether it also holds in subjects with no evidence of 
liver disease.
Table 11 ADH activity, LAA content and 
liver histology in 12 patients 
with non-alcoholic liver disease
ADH at pH 8.8 LAA Q
(u/g protein) (pg/lO WBC) Histology Jaundice
20.7 34.6 Portal Cirrhosis +
12.9 17*7 Infectious hepatitis +
(minimal changes)
12.8 26.7 Fatty infiltration
(? toxic factor)
12.2 23.7 Mild non-specific inflammation
10.7 23*6 Biliary stasis - obstruction +
8.9 19«0 Chronic agressive hepatitis +
8.4 7.2 Cirrhosis +
5*8 7.0 Secondary carcinoma
5*7 11*3 Primary biliary cirrhosis +
5.1 15*4 Chronic active hepatitis
4-9 10.5 Secondary carcinoma +
2.2 6.3 Secondary Carcinoma
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Correlation between ADH activity and LAA content in 
12 patients with non-alcoholic liver disease.
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SECTION 1 (ii^
Ascorbic Acid and Ethanol Metabolism*
As it is unethical to subject healthy individuals to hepatic 
biopsy when there is no clinical evidence of liver disease, and hepatic 
histological results are not required for diagnosis, indirect methods 
must be used to establish whether ADH activity is related to ascorbic 
acid status in subjects with no evidence of liver disease, ADH is the 
initial and rate limiting enzyme in the major pathway of ethanol 
oxidation^, therefore any agent which affects its activity should alter 
the rate of ethanol clearance from the blood. The possibility of 
ascorbic acid • status affecting the activity of ADH was therefore 
studied indirectly in healthy volunteers by measuring the rate of 
clearance of ethanol from the blood, before and after oral ascorbic 
acid.
Methods,
The rate of clearance of ethanol from the blood was measured in 
eleven healthy male volunteers,' before and after treatment with an 
oral dose of lg ascorbic acid daily for two weeks. The subjects 
fasted overnight prior to measurement of ethanol clearance rates.
Between 9*30 a.m, and. 10 a.m. they drank 150ml vodka diluted with 
lemonade, and blood samples were removed at hourly intervals for four 
hours. Blood ethanol and the rate of ethanol removed from the blood 
were determined as previously described. In humans the rate of ethanol 
cleared from the blood in mg ethanol/lOOml blood/hour is termed the 
/360^. LAA was also measured before and after ascorbic acid treatment. 
Results.
Except in two subjects (nos 1 and 2), there was a significant 
increase in LAA concentration after ascorbic acid treatment (P <0.02,fig 13). 
Similarly there was a significant rise in (360 after ascorbic acid
/360(mg%per h.)
20—1
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AfterBefore
Leucocute Ascorbic Acid 
3 (yug/108 W BC)
Ig A .A -  
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Fig , 13
060 and LAA content before and after oral 
supplementation of Ig ascorbic acid for 2 weeks
treatment, a significant increase was obtained (P<0.05) after oral 
ascorbic acid. Using the method of least squares, a significant 
correlation coefficient was obtained when the 060 of each subject was 
plotted against its corresponding LAA concentration (r = 0.6, P < 0.005; 
fig 14).
Discussion.
The significant increase in 060 after ascorbic acid treatment 
indicates that increased LAA concentrations are associated with an 
increased rate of ethanol clearance from the blood. This could be due 
to increased activities of ADH, although the relationship found between 
ADH and LAA was only established in patients with liver disease, and 
may not necessarily hold in subjects with no evidence of liver disease.
Erom the results obtained in this study, it is impossible to 
exclude other factors that may be contributing to the increase in blood 
ethanol clearance rate. It is possible that other ethanol oxidizing 
enzymes may be increased by the ascorbic acid treatment, especially 
microsomal enzymes which have been previously shown to be affected by 
ascorbic acid status.. Alternatively altered renal clearance of ethanol 
may be contributing to the increase in 060.
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SECTION 1 (iii)
Relationship in Patients With Alcoholic and Non- 
Alcoholic Liver Disease and in Control Subjects.
As liver biopsy samples could not be obtained from subjects with 
no evidence of liver disease, the nature of the above relationship 
between ADH and LAA is still unclear. The possibility of obtaining 
normal liver samples from patients with duodenal ulcer prompted the 
present study. Its purpose was to investigate a control group of 
patients, and establish whether the above relationship also held in 
patients with no evidence of liver disease. At the same time, a 
larger group of patients with liver disease were studied to see if this 
relationship was also evident in patients with alcoholic liver disease. 
METHODS 
Patients
Thirty-five patients with clinical or biochemical evidence of liver 
disease were studied, in whom a liver biopsy was indicated for diagnostic 
purposes. The biopsy was obtained using a Menghini needle and half the 
sample was fixed in formal saline for histological purposes and the 
other half placed on ice for alcohol dehydrogenase determination. The 
relevant history of alcohol intake was noted for each patient and they 
were divided into groups depending on this intake.
The classification of individuals with regard to their drinking 
history can only be done on a purely arbitrary basis. Individuals who 
regularly consumed over four pints of beer, or the equivalent in spirits, 
on more than four occasions a week were considered moderate drinkers. 
Those who indulged in almost daily consumption of large quantities of 
alcohol to the extent that their physical and/or mental well-being was 
impaired were placed in the alcoholic/heavy drinker group.
Control subjects.
Wedge liver biopsies were obtained during surgery for duodenal
ulcer in ten subjects with no clinical or biochemical evidence of 
liver disease; prior consent for the removal of the biopsies was 
obtained. No morphological changes were evident on histological 
examination of the liver biopsies; liver function tests were normal 
and there was no history of excessive alcohol consumption in these 
subjects.
Effects of in vitro ascorbic acid
Ascorbic acid solutions neutralised with NaOH and with final 
concentration in the range of 0.5mM to 10mM were added to the alcohol 
dehydrogenase assay system and alcohol dehydrogenase determined as above. 
Biochemical tests of Liver Function
Liver function tests were performed on all the subjects studied.
These included serum albumin, globulin and bilirubin levels, serum 
activities of alkaline phosphatase and alanine and aspartate transferases. 
Statistical methods
The significance of results was tested using the Students t test 
and Mann-Whitney U test.
Results
Biochemical tests of hepatic function in the patients with liver 
disease, divided according to their drinking history, are given in tables 
12, 13 and 14* The activity of hepatic alcohol dehydrogenase, 
concentration of leucocyte ascorbic acid and summary of hepatic histology 
for each of the patients with liver disease are given in tables 15> 16 
and 17. In the non drinker group (table 15) * there is one subject with 
alcohol dehydrogenase activity within the normal range of the present 
study (32-62 TJ/g protein) and 5 subjects whose leucocyte ascorbic acid 
concentration falls within the normal range (18-30 ng/10 WBC). Low 
alcohol dehydrogenase activities are associated with low concentrations 
of leucocyte ascorbic acid in this group, but it is difficult to relate
Table 12 Biochemical tests of hepatic function
in 10 non drinkers -with liver disease
Patient
No.
ASTa 
(iu/l)
T-
ALT Bilirubin 
(iu/l) (mg/l00ml)
Alkaline 0
Phosohatase
Albumin
(g/lOOml)
Globulin
(g/lOOml)
1 135 112 0 .6 85 3*4 3.9
2 19 15 0 .2 5 3*6 5.8
3 83 108 8 .6 19 3.6 3.0
4 76 49 3 .2 25 3.4 3.6
5 106 230 11 .3 15 3.9 3.8
6 236 114 2.4 110 3.1 2.3
7 528 368 20.0 65 3.1 4.9
8 34 31 1.0 15 -.. - 2.9 . 3.6
9 168 112 48 320 3.8 3.9
10 65 32 1.1 70 3.3 3.1
Normal
Range 13-42 11-55 0.2-1.0 3-16 3.6-5.2 1.9-3.7
1°
Abnormal 80 60 70 70 60 50
a Aspartate transaminase
b Alanine transaminase
c King-Armstrong units
Table 13 Biochemical tests of hepatic function in 10 
moderate drinkers vrith liver disease
Patient
No.
ASTa 
(iu/l)
ALTb
(iu/l)
Bilirubin 
(mg/lOOml)
Alkaline Q
Phosphatase
Albumin
(g/lOOml)
Globulin
(g/lOCml)
1 35 24 5.3 8 5.4 2.4
2 116 35 4*6 36 2.3 4.2
3 229 499 6 .8 22 4.4 4.3
4 60 35 0.9 16 3*7 4.9
5 96 82 2.4 32 4*2 3.5
6 58 33 0.7 17 2 .2 3.3
7 19 10 0.3 20 3*1 3.8
8 76 44 1.9 20 2 .4 3.2
9 88 39 1.2 35 3*5 5.0
10 45 13 1.4 ’ ' 25 .... 2.7 3.0
Normal
Range 13-42 11-55 0.2-1.0 5-16 5.6-5.2 1.9-3.7
1 80 Abnormal 30 70 80 70 50
a Aspartate transaminase
b Alanine transaminase
c King-Armstrong units
able 14 Biochemical tests of hepatic function in 15
alcoholic/heavy drinkers with liver disease
Patient
17o.
ASTa
(iu/l)
ALTb
(iu/l)
Bilirubin
(mg/lOOml)
Alkaline
Phosphatase
Albumin
(g/lOOml)
Globulin
(g/lOOml)
1 55 41 0.5 28 3 6 . 5
2 52 42 0.4 15 1.5 2.9
3 70 33 0.7 8 4-0 4.1
4 34 43 0.5 12 4*4 3.6
5 79 56 3*3 19 3.6 3.4
6 50 40 0.5 12 3.0 3.1
7 49 29 2 . 2 15 2 .5 3*1
8 64 87 0.7 20 3-7 2.2
9 251 371 2.2 8 3.7 5.8
10 960 380 2.4 18 _ _ 2.9
11 80 10 2.5 22 2.8 3-2
12 67 10.2 42 4.5 2-5
13 .54 17 3.8 13
14 68 25 6.7 41 2.0 4-2
15 9° 100 30.4 17 2.5 4-5
Normal
Range 13-42 11-55 0.2-1.0 3-16 3.6-3-2 1.9-3.7
d
P 93 
Abnormal 47 60 47 47 33
a Aspartate transaminase
b Alanine transaminase
c King-Armstrong units
Table 15 ADH activity, LAA levels and hepatic histology 
in 10 non drinkers with liver disease
ADH at pH 11.0 LAA Q 
Sex (u/g protein) (|o^ /l0 WBC) Histology Jaundice
1. M 40.2 46.9 Primary biliary cirrhosis -
2 . M 29 .0 23-7 Mild non specific 
inflammation
3- P 20 .0 25.O Viral hepatitis +
4- M 17 .8 25 .6 Biliary obstruction +
5- P 17.1 17-7 Infectious hepatitis +
6 . M 16.3 7-2 Histiocytic infiltration - -
7. F 16 .1 19 .0 Chronic aggressive 
hepatitis
+
8. M 11.7 15.9 Fatty infiltration -
9* P 8.9 11.3 Primary biliary cirrhosis +
10 M 1 .1 6 .3 Secondary carcinoma
Tahle 16 pjjr activity, LAA levels, and hepatic 
histology in 10 moderate drinkers v;ith 
liver disease.
ADH at pH 11*0 LAAQ 
Sex (U/g protein) (|Jg/lO ¥BC) Histology Jaundice
1. M 37.2 41.5 Normal +
2. M 37.2 34.6 Cirrhosis +
5. M 29 .0 15.7 Viral hepatitis +
4. M 25.3 29.0 Patty infiltration
5- M 22.4 12.3 Infectious hepatitis +
6. M 20.1 6.9 Fatty infiltration
7- M 17.9 26.7 Fatty infiltration -
8. M 11.0 7.0 Cirrhosis -
9. F 10.2 15.4 Chronic a.ctive hepatitis
10. F 5.5 9.1 Cirrhosis +
Table 17 ADH activity, LAA levels, and hepatic histology
in 15 alcoholic/heavy drinkers with liver disease.
Sex
ADH at pH 11.0 
("d/g protein)
LAA 
(pg/108 WBC) Histology Jaundice
1. M 42 .6 19.3 Granulomatous condition -
2. M 34.2 26.5 Fatty infiltration -
3. F 32 .6 24.9 Alcoholic hepatitis -
4* M 28.1 22.5 Portal cirrhosis -
5- M 27.3 23 .0 Cirrhosis + alcoholic 
hepatitis
+
6. M 2 5 .0 32 .0 Alcoholic hepatitis -
7* M 19-3 12.3 Fatty infiltration +
8. M 1 5 .0 12.2 Fatty infiltration -
9. M 12.5 6 .4 Cirrhosis +
10. M 12.2 2 4 .0 Alcoholic hepatitis -
11. M 8.9 7.6 Acute + chronic alcoholic 
hepatitis
-
12. M 5.9 4.0 Bile duct obstruction + 
Alcoholic hepatitis
+
13. M 4.8 5.3 Cirrhosis + alcoholic 
hepatitis
+
14. F 2.9 13.7 Cirrhosis + alcoholic 
hepatitis
+
15. M 2.1 3.7- Advanced cirrhosis + acute 
alcoholic hepatitis.
+
these parameters to the extent of liver damage as assessed by histology. 
In the moderate drinker group (table 16) two subjects have alcohol 
dehydrogenase activities within the normal range and four subjects have 
leucocyte ascorbic acid concentrations within the normal range. Again 
low alcohol dehydrogenase activities are associated with low leucocyte 
ascorbic acid concentrations, but there is no clear relationship between 
these two parameters and hepatic histological findings.
With regard to the alcoholic/heavy drinker group (table 17), three 
subjects have normal alcohol dehydrogenase activities and seven subjects 
have concentrations of leucocyte ascorbic acid within the normal range. 
Alcohol has contributed to hepatic pathological changes in this group, 
as there are nine subjects with histological changes consistent with 
alcoholic hepatitis and six of these individuals have the lowest 
activities of hepatic alcohol dehydrogenase in this group. Hepatic 
histological changes can be related to alcohol dehydrogenase activity, 
as the three lowest activities of alcohol dehydrogenase are found in 
subjects with cirrhosis and alcoholic hepatitis wno were also jaundiced. 
No relationship between alcohol dehydrogenase activity and either serum 
aspartate transferase or serum alanine transferase was obtained.
In table 18» the alcohol dehydrogenase activity and leucocyte 
ascorbic acid concentration in the groups with liver disease are 
compared with values in the control subjects with no liver disease.
There was no significant difference in alcohol dehydrogenase activity 
between the groups with liver disease, but alcohol dehydrogenase 
activity was significantly lower (p< 0,001) in these groups compared 
witn the control group when the Students t test was applied. This was 
also significant using the Mann-Whitney U test (p< 0.002),
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The leucocyte ascorbic acid concentration of the alcoholic/heavy 
drinker group was significantly lower (p<0.02) than that of the 
control group, using the Students t test, but this was not significant 
when the Mann-Whitney U test was applied.
A scatter diagram obtained by plotting the alcohol dehydrogenase 
activities of the 35 patients witn liver disease against their 
corresponding leucocyte ascorbic acid concentrations is illustrated 
in figure 15* A straight line correlation was found with r = 0.77 
a significance of p< 0*001. This was repeated with the liver disease 
patients divided according to their previous drinking histories and in 
each group a significant correlation coefficient was obtained (figure 16). 
Significant correlation coefficients of r = 0.873 (p<0.00l) for the 
non drinkers, r = 0.759 (p<0.02) for the moderate drinkers and 
r = 0.702 (p< 0.005) for the alcoholic/heavy drinkers were obtained.
An insignificant correlation coefficient of r = 0.352 was found for 
the control subjects with no liver disease.
The in vitro addition of ascorbic acid in the range of 0.5inM to 
lOmM final concentration had no effect on alcohol dehydrogenase activity. 
Discussion
The low hepatic alcohol dehydrogenase activities found in the
groups of patients with liver disease is in agreement with the results
137of Hgueroa and Klotz who demonstrated low alcohol dehydrogenase 
activities in patients with cirrhosis and jaundice. In the present 
study, when alcohol dehydrogenase activity, leucocyte ascorbic acid 
concentration and extent of liver damage (as assessed by hepatic 
histology) are considered in each patient with liver disease, it is 
apparent that patients with changes in liver histology associated with
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/
cirrhosis and alcoholic hepatitis who are also jaundiced, generally
have low alcohol dehydrogenase activities and concomitant low concentrations
of leucocyte ascorbic acid. It is possible that jaundice itself may
140interfere with ADH, as bilirubin has been shown to inhibit ADH in vitro •
As alcohol dehydrogenase activity in the moderate and non drinker
groups is similar to that in the alcoholic/heavy drinker group, alcohol
consumption per se does not seem to alter alcohol dehydrogenase activity.
In the present study the concentration of leucocyte ascorbic acid
in the alcoholic/heavy drinker group is significantly decreased compared
to that of the control group when the Students t test is applied, but
there is no significant difference in leucocyte ascorbic acid concentration
between the moderate and non drinker groups and the control group. The
Mann-V/hitney U test failed to demonstrate a significant difference between
the leucocyte ascorbic acid concentrations of the groups with liver
disease and the control group. This suggests that the significant
difference found between the leucocyte ascorbic acid concentration of
the alcoholic/heavy drinker group and the control group, when the Students
t test was applied, is of little real significance. As the control group
consists of subjects with duodenal ulcers, who tend to have lower than
141normal leucocyte ascorbic acid concentrations , it is possible that this
may contribute to the insignificant difference in leucocyte ascorbic acid
concentration between the groups studied.
Although ascorbic acid deficiency is associated with decreased
activities of microsomal drug hydroxylating enzymes and electron
109transport components in guinea pigs , the nature of the relationship 
between hepatic alcohol dehydrogenase and leucocyte ascorbic acid is 
unclear. In the patients with liver disease (figure 15). there is a 
significant•correlation between alcohol dehydrogenase activity and the
concentration of leucocyte ascorbic acid, but this is not found for the 
control subjects. The range of the activity of alcohol dehydrogenase 
in the control subjects is approximately 32 — 62 U/g protein, whereas 
in the liver disease patients it is approximately 1 - 4 5  tf/g probein 
(figure 16), The insignificant correlation found between hepatic 
alcohol dehydrogenase activity and the concentration of leucocyte 
ascorbic acid in the control group, may be explained by this difference 
in the range of activities of alcohol dehydrogenase between the 
control and liver disease groups, although the presence of liver disease 
may be the determining factor.
In vitro addition of ascorbic acid in the concentrations described 
has no effect on alcohol dehydrogenase activity; consequently ascorbic 
acid does not seem to be involved in the alcohol dehydrogenase reaction. 
This has been confirmed previously in vivo, as there is no correlation 
between alcohol dehydrogenase activity and ascorbic acid status in the 
ascorbic acid deficient guinea-pig. The presence of liver disease is 
therefore an important factor in this correlation found in the human.
The relationship between alcohol dehydrogenase activity and the 
concentration of leucocyte ascorbic acid also holds when the subjects 
with liver disease are divided according to their previous alcohol 
intake (figure 16) • Alcohol intake does not seem to be responsible 
for this relationship as a significant correlation is also found in the 
non drinker group.
It is concluded that the correlation between alcohol dehydrogenase 
activity and leucocyte ascorbic acid concentration found in the present 
work is probably a consequence of liver disease, as opposed to any 
specific effect of ascorbic acid status or alcohol consumption on 
alcohol dehydrogenase activity.
SECTION 2 
Incidence of Atypical ADH in 
Scottish Population.
Human ADH exists in multimolecular forms, at least seven isoenzymes
15
can be distinguished by electrophoretic and chromatographic methods •
Schenker et al^ have isolated, purified and determined the subunit
composition of six of these isoenzymes. These authors have suggested
that the isoenzymes are formed by combinations of three subunits
designated A, B and B^ to give six dimers AA, BB, AB, Bb\ B^B1 AB1.
17Berger et al have shown that subunit B can exist in two forms termed
and B^ . Diese subunits differ in one amino acid residue, which is
located in a region of the subunit which corresponds to the coenzyme
binding site of horse ADH. B^ is considered the subunit which is
responsible for the atypical catalytic properties discussed below.
18Von Wart burg et al have shown that ADH exhibits a polymorphism,
which is revealed by a bimodal distribution of the enzyme in a
population. A screening test has been devised to differentiate between
19the normal and atypical enzyme • . Die normal enzyme has a pH optimum 
of 10.8 while the atypical enzyme has a pH optimum of 8.5.
The screening test involves measurement of ADH activity at pH 8.8 
and pH 11.0. The quotient formed by dividing the activity at pH 11.0 
by that at pH 8.8, known as Q pH, is used to differentiate between the 
normal and atypical enzyme. Q pH is greater than one for the normal 
enzyme, and less than one for the atypical enzyme.
Die incidence of atypical ADH in a Scottish population was studied 
using the above screening method.
Methods.
ADH activity was measured at pH 8.8 and pH 11.0, as described 
previously, in liver biopsy samples from the 35 patients with liver 
disease, and the 10 subjects with duodenal ulcer, who were studied in
the previous section. The frequency distribution of Q pH was plotted 
for the 45 samples.
Results.
The results of the screening test on the 45 liver biopsy specimens 
are shown in figure 17. Two subjects with atypical ADH were found, as 
there are two biopsies with Q pHcl. Of the two subjects with the 
atypical form of ADH, one was from the control group with no evidence 
of liver disease, and the other was from the group with liver disease.
Q pH follows a bimodal distribution.
Discussion.
Die frequency of atypical ADH in the Scottish population studied 
was 2 out of 45 subjects (fig. 17)» which is approximately a 4% incidence. 
This agrees with a study of a London population, which gave a frequency 
of 2 out of 50 subjects witn atypical ADH19. These same workers showed 
that atypical ADH was present in 20% of a Swiss population (12 out of 
59 subjects)19.
49Biwards and Evans revealed a slightly higher incidence of the 
atypical enzyme in a Liverpool population (approximately 8%), but as this 
only represented 2 out of 23 subjects, the small population studied may 
have contributed to this apparent higher incidence.
The bimodal distribution of the atypical enzyme found in the London
19and Swiss populations by Von Wartburg and Schurch , and in the Scottish 
population in the present study differs from that obtained by Ugarte et
1 A 0
al in 80 Chilean alcoholics. These authors showed a trimodal 
distribution of Q pH and also suggested that atypical ADH is more common 
in alcoholics with steatosis or cirrhosis, compared with alcoholics 
with normal histology, unfortunately the statistical significance of 
these results is questionable. In the present study, no increased
10i
N
n = 45
4h
2-\
02 04 0-6 0« >0 1-2 14 1-6 1-8 20 2-2 24 QpH
Fig . 17
Frequency distribution histogram of atypical ADH 
in 45 liver biopsies from a Scottish poulation. 
QpH< I for atypical ADH.
incidence of the atypical enzyme was evident in the patients with liver 
disease, al though the population studied is probably too small to 
observe any possible increased incidence.
It is of interest that Bgarte et al1^  found a trimodal
143distribution of normal and atypical ADH in their study, as Smith et al
have proposed a genetic model in which three groups of individuals
would be expected from considerations of subunit composition. Their
model suggests that two alleles occur at the gene locus coding for
subunit B, and these alleles are responsible for the synthesis of
either the normal (B^ ) or atypical (B^ ) subunit. Three groups of
individuals are expected with respect to their B subunit composition,
homozygotes with subunit B^ only, homozygotes with subunit B^ only and
heterozygotes with subunits B^ and B^ .
17Berger et al have confirmed this proposed genetic model by showing
that isoenzyme BB, isolated from both normal and atypical phenotypes,
contains subunits B^ and B^  in the atypical isoenzyme, and only subunit
B^ in the normal isoenzyme. B^ is therefore responsible for the
atypical characteristics. Isoenzymes BB from human liver can therefore
contain three isoenzymes with the composition °r ^2^2*
143This agrees with the genetic model of Smith et al • In view of the 
low estimated frequency of the allelic gene bg, an extremely low 
frequency of homozygous individuals with genotype b^b^ and isoenzyme 
composition B^B^ would be expected. Large numbers of liver samples 
would therefore need to be screened before this trimodal distribution 
can be detected.
\SECTION 3.
ETHANOL OXIDIZING ENZYMES 
IN PATIENTS WITH LIVER DISEASE
The possible involvement of MEOS in ethanol metabolism has been 
previously studied in man by Mezey and Tobon*^# who measured the rate 
of ethanol clearance from the blood and the activities of ADH and the 
NADIH dependent ethanol oxidizing system, in recently drinking alcoholic 
patients without liver disease and in non-drinking controls. The 
rate of ethanol clearance and the activity of the NADPH dependent 
ethanol oxidizing system were increased in the alcoholic patients; 
but although the rate of ethanol clearance returned to normal after 
7 days abstinence from ethanol, the activity of the NADPH dependent 
ethanol oxidizing system only decreased significantly after 21 days 
abstinence from ethanol.
Non parallel changes in ethanol clearance rates and the activity
of the NADPH dependent ethanol oxidizing system have also been shown in
145phenobarbitone treated alcoholic patients who had no evidence of 
liver disease. ADH activity and NADPH dependent ethanol oxidizing 
system activity, as well as ethanol clearance rates, were measured in 
alcoholics before and after phenobarbitone administration. Ethanol 
clearance rates were increased, but no change in the activities of ADH 
or NADPH dependent ethanol oxidation was apparent.
Previous investigators have shown a decrease in ADH activity in
137patients with liver disease , but no measurement of the other 
enzymes involved in ethanol metabolism was undertaken. In the present 
study, ADH, catalase and the NADPH dependent ethanol oxidizing system 
were measured in hepatic biopsies from patients with liver disease, 
and the activities compared with those in control subjects with no 
liver disease.
Methods
Patients
Nine patients with clinical or biochemical evidence of liver 
disease were studied: in each case a liver biopsy was indicated for 
diagnostic ourposes. The history of alcohol consumption of each 
patient was noted. No patient had consumed alcohol for at least 
one week prior to biopsy. Patients receiving" drugs known to induce 
hepatic microsomal enzymes were excluded.
Control subjects
Liver biopsies were obtained during surgery for duodenal ulcer 
with the informed consent of 7 subjects with no clinical or biochemical 
evidence of liver disease. Histology showed no morphological changes 
in the liver, and no history of excessive alcohol consumption was found 
in this group of patients.
Ehzyme determinations
ADH, catalase and NADPH dependent ethanol oxidation were measured 
in each biopsy, using previously described methods.
Results
The history of alcohol consumption, biochemical tests of liver 
function and hepatic histology of the 9 patients with liver disease 
axe summarised in Table 19. Histology indicated that alcohol played 
a major role in the pathological changes in the livers of patients with 
an alcoholic or heavy drinking history.
The activities of the ethanol oxidizing enzymes measured in the 7 
control subjects and 9 patients with liver disease are given in Tables 
20 ana 21 respectively. Control subject number 4 is a carrier of the 
atypical form of ADH (Table 20). The activities of the ethanol 
oxidizing enzymes in the two groups are compared in Table 22 > with
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enzyme activities expressed in terms of protein concentration. Alcohol 
dehydrogenase and catalase activities were significantly lower, and 
the activity of the NADPH dependent ethanol oxidizing system was 
significantly higher in the patients with liver disease, when the Students 
t test was applied. The activity of the NADPH dependent ethanol 
oxidizing system was also significantly higher in the liver disease group 
than that in the control subjects, when the Kann-Vhitney TJ test was 
used (P<0.02).
The mean activity of the NADPH dependent ethanol oxidizing system
found in the control subjects of the present work (4.6 + 2.4 nmoles/mg
protein/min) is similar to that found by Mezey and Tobon"^^ in their
control subjects (4*2 + 1.0 nmoles/mg protein/min).
The activities of the ethanol oxidizing enzymes in the control and
liver disease groups are compared in Table 23, with enzyme activities
expressed in tgrms of liver weight. ADH and catalase activities were 
\
significantly lower, and the activity of the NADPH dependent ethanol 
oxidizing system was significantly higher in the patients with liver 
disease.
Discussion
Although liver biopsy samples are of relatively small size (20-40 mg),
histological findings are generally representative of changes in the whole
157liver. Soloway et al have demonstrated that the sampling error in 
multiple simultaneous biopsies was very small in cases of hepatitis, 
although this error was larger in cases of cirrhosis.
In the analysis of enzyme activities in liver biopsies the choice 
of reference for expressing enzyme activity is important. The activity 
can be related to wet weight, protein or RNA or DNA content, or to the 
number of cells in the biopsy specimen. In the present study enzyme
activities v^re expressed in terms of both wet weight and protein
content of the liver biopsy specimen. The method of Lowry et
used for the determination of the protein content of the biopsy
specimens measures the number of tyrosine residues in a protein.
158Fibrotic tissue contains very little tyrosine and will therefore
nat interfere with the calculation of enzyme activity, when it is
expressed in terms of protein content. It is however useful to use
rriore than one reference for the calculation of enzyme activities as
this will minimise error in the interpretation of results from liver
biopsies of patients with different types of liver disease.
A limitation of cytochemical enzyme determination in liver
biopsy specimens is that no information is obtained about the
localisation of enzyme activity in the tissue. Some cells may have
a high enzyme content and thus give a false picture of the overall
activity in the liver. Histochemical methods are useful in tnat
3
they can localise the activity of enzymes but unfortunately yield 
poor Quantitation.
Although previous investigators have shown non parallel changes 
in the rates of ethanol clearance from the blood and the activity of 
the NADPH dependent ethanol oxidizing system,^4? ^ 5  they have mainly 
been concerned with the mechanism of increased ethanol clearance rates.
A possible mechanism for the maintenance of normal rates of ethanol 
clearance in patients with low ADII activities, is considered below.
The decrease in ADH activity shorn in the patients with.liver disease
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activity is decreased by approximately 50% in the nine patients with
liver disease. Although it is difficult to relate in vitro enzyme
activities with in vivo activities, this decrease may affect ethanol
22clearance rates as Goldberg and Rydberg have shown that inhibition 
of rat ADH with pyrazole reduces ethanol metabolism in vivo. Ethanol 
clearance rates were not measured in the present study, but other 
investigators have shown that ethanol clearance rates are unchanged in 
patients with liver disease.
There are two possible mechanisms for the maintenance of ethanol 
clearance rates in patients with liver disease. The first possibility 
is, that even with a 50% reduction in ADH activity measured in vitro, 
there is sufficient activity in vivo to maintain normal rates of 
ethanol metabolism. The second possibility is that other enzymes 
involved in ethanol oxidation may play a quantitatively more important 
role in patients with liver disease. The results obtained in the 
present study add weight to this second possibility.
42
In the proposed system of Carter and Isselbacher, NADPH
dependent ethanol oxidation takes place via NADPH oxidase activity
which produces this in turn is used in the peroxidative conversion
of ethanol to acetaldehyde, catalyzed by catalase. The decrease in
catalase activity shown in the liver disease group is probably not
great enough to affect its utilisation of as in the above proposed
system NADPH dependent ethanol oxidation is regulated by the activity
31of NADPH oxidase and its production of • The increase in NADPH
dependent ethanol oxidation in the liver disease patients may reflect 
an increase in the activity of NADPH oxidase.
There are several possible explanations for the increased activity
of the NADPH dependent ethanol oxidizing system found in patients with 
liver disease. In alcoholic hepatitis liver protein is decreased, 
and this could explain the increased activity of the NADPH dependent 
ethanol oxidizing system, when its activity is expressed in terms of 
protein concentration. Although, when its activity is expressed in 
terms of liver weight, it is still increased and differences in liver 
protein concentration are therefore unlikely to contribute to this 
increased activity.
Recent alcohol intake has also been shown to increase the activity 
of the NADPH dependent ethanol oxidizing system, but this again is 
an unlikely explanation for the increased activity found in the present 
study. There are three non drinkers in the liver disease group 
(subjects 4, 5 ani 6, Table 21 ) who also have high activities of the 
NADPH dependent ethanol oxidizing system.
The increase in the NADPH dependent ethanol oxidizing system may 
therefore be an adaptive increase because of low ADH activities in 
patients with liver disease, or may simply reflect increased cellular 
disruption.
149Schoene et al have measured cytochrome P-450 content and the 
activity of aminopyrine demethylase in human liver biopsies. They 
demonstrated that cytochrome P-450 content was decreased by 50% in 
severe hepatitis and cirrhosis. Similarly the rate of demethylation 
of aminopyrine was significantly reduced in severe liver disease. As 
cytochrome P-450 dependent systems are reduced in liver disease, it 
appears that the NADPH dependent ethanol oxidizing system is not 
cytochrome P-450 dependent and cannot be considered a *true' 
microsomal enzyme.
General Discussion
Assuming that an alcoholic consumes one bottle of spirits per day
over a period of several weeks during a drinking bout, the resulting
ethanol intake is 4*3 g/Kg body wt/day for a 70 Kg man. This is
calculated from the ethanol content of the spirit (40 g/lOOml), and
assumes that the bottle contains 750 ml snirit. As the LDcr. for a50
45single oral dose of ethanol is 4 g/Kg in the guinea pig , ethanol
pretreatment was achieved by administering an oral dose of 2.5 g
ethanol/Kg body wt/day for 14 days. Although the guinea pigs did not
ingest ethanol throughout the day, as would the human alcoholic, the
ethanol pretreatment they were given was as high and as near as possible
to the intake of an alcoholic.
The above ethanol pretreatment resulted in a significant reduction
in the extent of the redox state shift after ethanol administration,
compared with that in unpretreated control guinea pigs (tables3»4)*
This was not due to differences in blood ethanor^concentrations
between the ethanol pretreated and unpretreated control animals, as
the theoretical zero time concentration of ethanol in the blood (C ) was' o'
the same in both groups of animals (table 7)* Although the redox state
115
is important in the regulation of ethanol elimination in vivo , the 
approximately ten per cent decrease in the extent of the redox state 
shift after ethanol administration to ethanol pretreated guinea pigs, 
was too small to influence their rate of ethanol elimination in vivo 
(table 7)«
The decrease in the extent of the redox state shift after ethanol
administration, demonstrated in ethanol pretreated guinea pigs, may
represent metabolic adaptation to ethanol at the mitochondrial level.
53Previous work by Rawat and Kunyama showed that ethanol pretreated
mice have an increased mitochondrial permeability to NADH, Yidela et 
31al have also demonstrated that mitochondria isolated from ethanol
pretrea.ted rats have a faster rate of oxygen consumption, which 
suggests that they can reoxidise KADH at a faster rate. Although it 
is uncertain which of these mechanisms is operating in the ethanol 
pretreated guinea pig, "both will result in an increased rate of 
mitochondrial utilization of HADH. Reducing equivalents produced from 
ethanol oxidation will therefore be metabolized at a faster rate, 
resulting in the observed attenuation of the redox state shift in the 
present study.
As metabolic adaptation was achieved in guinea pigs after a 
relatively short period of exposure to ethanol, it is very likely that 
this can occur in man after exposure to comparable quantities of ethanol.
The relationship between ADH activity and LAA content found in 
patients with liver disease (figures 12, 15) was not found in subjects 
with normal liver histology (figure 16). As the addition of ascorbic 
acid in vitro to the human ADH reaction system had no effect on its 
activity, it is concluded that this relationship is a consequence of 
liver disease as opposed to any specific effect of ascorbic acid status 
on ADH activity. This is further confirmed by the observation that ADH 
activity of normal and ascorbic acid deficient guinea pigs is not 
related to their ascorbic acid status (table 5)»
' When ADH activity, LAA content and hepatic histology are compared 
in patients with liver disease, it is apparent that patients who are 
jaundiced and have changes in liver histology compatible with cirrhosis 
and alcoholic hepatitis, have very low ADH activities and LAA contents 
(table 17). This may be useful in the diagnosis of chronic liver 
disease, when a liver biopsy cannot be carried out. If a patient has 
jaundice and suspected liver disease, demonstrated by abnormal biochemical 
liver function tests, a very low LAA is a good indication of chronic liver 
disease.
As ADH does not depend on ascorbic acid for activity, it is
difficult to explain the increased rate of ethanol clearance from the
blood (p60) in man, after ascorbic acid supplementation (figure 13)*
As this increased rate is small and only represents 1-2 mg ethanol/100 ml
blood/hr, it may simply reflect an altered renal clearance of ethanol.
Alternatively it may be due to the enhanced activity of microsomal
enzymes capable of oxidizing ethanol, as microsomal enzyme activities
109have been shown to be dependent on ascorbic acid status , although 
ethanol clearance rates were not enhanced in ascorbic acid supplemented 
guinea pigs compared with ascorbic acid deficient animals (table 7)»
The difference in the effect of ascorbic acid on ethanol metabolism in 
man, and the guinea pig, may be due to variations in the extent of 
tissue saturation with ascorbic acid after oral supplementation. Tissue
saturation with ascorbic acid is attained at 260 pg ascorbic acid/g wet
107 8 99wt liver in guinea pigs and 50 pg/10 WBC in man ; from table 5 and
figure 15 it is obvious that tissue saturation had not been reached in
either the human volunteers or guinea pigs.
Although it is difficult to relate the in vitro activity of an
enzyme to its possible in vivo activity, the increase in t^ of diphenyl-
2
hydantoin in the ascorbic acid deficient guinea pig (table 1) is
probably due to a decrease in activity of microsomal drug metabolizing
enzymes. This is confirmed in table 6, where aniline hydroxylase
activity and cytochrome P-450 content are shown to be decreased in
123ascorbic acid deficient guinea pigs.‘ Wade et al showed that the
decrease in activity of microsomal enzymes, isolated from ascorbic acid
deficient guinea pigs, was not due to qualitative changes in the enzymes,
as there was no change in K for aniline or hexobarbitone.m
The 3&J° increase in t^ of DPH in the ascorbic acid deficient guinea
2
pig (table 1), compares with a 22% decrease in the activity of aniline 
hydroxylase and a 24% decrease in cytochrome P-450 content (table 6).
Unlike DPH, which is metabolized entirely by the microsomal drug
150metabolizing system, Lieber and De Carli consider that 2CP/o of ethanol
metabolism in vivo is carried out by MEOS. As the increase in DPH ti.
2
is due to decreases in microsomal enzyme activities, a similar 36%
decrease in the rate of ethanol elimination by microsomal pathways will
only give rise to a 7»2% decrease in the overall rate of ethanol
metabolism* This represents a decrease of approximately 2.1 mg/100 ml/hr
in the rate of ethanol elimination from the blood in the normal guinea
pig, whose rate of ethanol elimination is 29.3±2.7 mg/100 m l/hr (table 7).
Unfortunately this decrease is within the S.D. of the measurement of the
rate of ethanol elimination in vivo and would probably not be detected.
A further problem is that MEOS activity in vitro was unchanged in the
ascorbic acid deficient animal. From these theoretical considerations
it is therefore difficult to arrive at any firm conclusions regarding the
extent of MEOS activity in vivo.
The in vivo significance of MEOS has been studied using inhibitors
of the microsomal drug metabolizing system, in an attempt to establish
the extent of microsomal involvement in ethanol metabolism. Khanna and 
120Kalant using the microsomal enzyme inhibitor SKF 525-A showed that it 
had no effect on the rate of ethanol clearance from the blood of rats 
and the whole body of mice. These authors concluded that ethanol was 
therefore not metabolized to any significant extent by microsomal enzymes. 
The above findings are questionable, as some drugs (especially those with
type II binding characteristics) are metabolized by enzymes which are
151 37relatively insensitive to this inhibitor • Rubin et al have shown
that ethanol produces a modified type II binding spectrum. • Lieber and 
152De Carli have also shown that MEOS activity is not affected by 
SKF 525-A in vitro, and conclude that work using this inhibitor to 
establish the extent of microsomal involvement in ethanol metabolism in 
vivo is invalid.
In the present study the use of non specific inhibitors has been 
avoided, with the use of the ascorbic acid deficient guinea pig as an 
animal model for studies on the effect of decreased microsomal enzyme 
activities on ethanol metabolism. Although in vivo studies were 
inconclusive, measurement of cytochrome P-450 content and aniline 
hydroxylase activity in vitro showed a significant decrease in the 
ascorbic acid deficient guinea pig, whereas MEOS activity was unchanged 
(table 6). As aniline is a type II substrate and aniline hydroxylase 
is dependent on cytochrome P-450 for its activity, ethanol with its 
modified type II properties should behave similarly with respect to 
requirement of cytochrome P-450 for MEOS activity.
After phenobarbitone treatment, aniline hydroxylase activity and 
cytochrome P-450 content were increased by 30 and 60 per cent respectively 
in guinea pigs, but MEOS activity and the rate of ethanol clearance from 
the blood were unchanged, (tables 9 and 10). As MEOS activity was not
induced by phenobarbitone and was not dependent on cytochrome P-450 
content, it does not appear to have properties associated with 'true* 
microsomal enzymes.
In human studies MEOS activity, measured as NADPH dependent ethanol 
oxidizing system activity, was increased in patients with liver disease 
(tables 22 and 23), although Schoene et al^^ have shown that cytochrome 
P-450 content and aminopyrine demethylase activity are reduced in chronic 
liver disease. Prom these studies it is again apparent that MEOS 
activity is not dependent on cytochrome P-450 for activity.
As MEOS does not show changes in activity similar to established
microsomal drug metabolizing enzymes, and is not dependent on cytochrome
P-450 for activity, it cannot be considered a 'true* microsomal drug
metabolizing enzyme. MEOS activity is therefore more likely to be a
product of NADPH oxidase and catalase activities, rather than that of a
45distinct microsomal oxidase .
The increase in the activity of the NADPH dependent ethanol oxidizing 
system in patients with liver disease may reflect an increase in NADPH
oxidase activity, as this is considered the rate limiting enzyme in the
31 39above alternative pathway to MEOS . Lieber and De Carli have shown
that chronic ethanol treatment results in an increase in NADPH oxidase
activity in rats, and they suggest that the increased production of
by this increased enzyme may play a role in the pathogenesis of liver
154damage via enhanced lipid peroxidation. Lundquist has suggested that 
under pathological conditions an increase in the breakdown products of 
purine metabolism might (presumably via the xanthine oxidase system) 
give rise to ^ 0 2  formation, although this system has not been quantitated.
Glutathione peroxidase, which utilizes most of the HgOg generated outside
155 156of the peroxisomes , is also reduced in liver disease • Under
pathological conditions the above systems can all give rise to increased
amounts of HgC^* and may contribute to the pathogenesis of liver damage
via enhanced lipid peroxidation. The increase in NADPH.dependent ethanol
oxidizing system activity, in patients with liver disease, may therefore
reflect the increase in pathological changes taking place.
In conclusion,when ADH activity is normal, as in the guinea pig
experiments, no further enzyme systems appear to be required for ethanol
metabolism; although in patients with liver disease, where ADH activity
is reduced by 50 per cent, other enzymes may play a quantitatively more
important role in ethanol metabolism, as ethanol clearance rates are
unchanged in these patients^^* It is suggested that the increase
in the activity of the NADPH dependent ethanol oxidizing system in
patients with liver disease may be an adaptive increase, which compensates
for the low ADH activities found in these patients. Normal rates of
ethanol metabolism can thus be maintained.
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